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Abstract 
The BRAF oncogene demonstrates a characteristic mutation (V600E) in a 
significant fraction of cutaneous melanomas, leading to constitutive activation of the 
MAP kinase pathway. This genetic lesion endows tumor cells with proliferative and 
survival advantages, and metastatic melanoma patients treated with the 
BRAF(V600E)-specific inhibitor, Vemurafenib, have shown dramatic clinical 
responses. Here, I show that BRAF(V600E) induces transcription of the IL-1α and 
IL-1β genes in both melanocytes and melanoma cell lines and that this upregulation 
is specifically abrogated by targeted BRAF(V600E) inhibitors. Furthermore, 
treatment of melanoma tumor-associated fibroblasts (TAFs) with IL-1α/β 
significantly enhanced the ability of TAFs to suppress the proliferation and function 
of melanoma antigen-specific cytotoxic T cells. IL-1α/β treatment of TAFs 
upregulated multiple immunosuppressive factors, including COX-2 and the PD-1 
ligands PD-L1 and PD-L2. Specific BRAF(V600E) inhibitors largely abrogated the 
ability of melanoma cells to confer T cell-suppressive properties on TAFs. These 
results support a model in which BRAF(V600E) promotes immune suppression in 
the melanoma tumor environment through an IL-1-mediated mechanism involving 
resident stromal fibroblasts. Based on these findings, combination therapies 
involving targeted BRAF inhibition and T cell-based immunotherapies are 
warranted.
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Chapter 1 
General Background 
 
Melanoma 
Somatic pigment cells, or melanocytes, can accumulate mutations and transform 
into malignant melanoma. Pigment cells are found throughout the body. Commonly 
known to be found in the cutaneous junctional region between the dermis and 
epidermis, and within hair follicles, these cells also line the mucosal membrane of 
the intestine, the leptomeninges, and reside in the eye and the inner ear. 
Melanocytes in all of these tissues can develop into melanoma and transform into 
lethal malignancies (Figure 1). 
 
Malignant melanoma spreads throughout the body, establishing itself in vital organs, 
and ultimately forming large masses, or tumors, that interfere with necessary 
functions. Because of this behavior, melanoma is a lethal disease. Diagnosis at 
early stages of progression allows surgical resection of the primary tumor and, if 
removed prior to metastasis, further risk is highly diminished. In fact, 90% of 
melanoma cases treated at the earliest primary stage spared the lethality of 
progressive disease for at least 20 years[1]. However, if surgery or detection is 
delayed, most cutaneous melanomas metastasize first to draining lymph nodes and 
may reach almost every site in the body. Patients with stage IV disease with 
visceral organ metastases have a 5-year median survival rate of only 10%[1]. 
Multiple clinical trials have demonstrated that melanoma is highly resistant to 
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chemotherapy; thus, alternative treatment modalities have generally been used to 
treat patients with this disease. Melanoma is the ultimate cause of death for 8,000-
9,000 people in the United States each year[2]. The number of deaths has been 
increasing despite efforts to promote preventative behaviors, early detection and 
aggressive therapy.  
 
Treatments for metastatic melanoma either directly target the tumor cells or activate 
an immune response against the tumor[3]. It is well-known that, for melanoma, 
conventional alkylating chemotherapy, typically dacarbazine or temozolomide, has 
low response rates (at best, 15-20%) and is not curative [2,4]. However, 
immunological interventions can achieve long-lasting durable remissions. Numerous 
immunological interventions have been conceived and many of them tested, but few 
have been approved for use by the United States Food and Drug Administration. 
Only Interkeukin-2 (1998) and Interferon alfa-2b (1995) are approved for use[3,5]. 
The mechanism of action of both these cytokines is understood to be the activation 
of tumor infiltration lymphocytes (Til)[6]. 
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Figure 1 Melanoma Progression Schematic Diagram 
 
A benign nevus situated at the dermo-epidermal junction progresses to metastatic 
melanoma. The process is typified by a stage-wise progression to dysplastic Nevus, 
a Radial Growth Phase, a Vertical Growth Phase, prior to metastasis[7]. (Adapted 
from Miller et. al. 2006) 
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Immunotherapy 
Melanoma tumors sometimes contain large numbers of infiltrating immune cells. Of 
special interest are Til that have the potential to kill tumor cells in specific fashion 
throughout the entire body. The ability of the immune system to target cancerous 
cells avails diverse opportunities to reduce patient disease burden, extend life, and 
even cure melanoma. The ability of the adaptive immune system to increase the 
rapidity and magnitude of the T cell immune response upon serial exposure to 
specific targets is presumed to allow for long-term control of cancer cell numbers, in 
this case, providing a functional cure.  
 
Considering the exceptional ability of an intact immune system to protect humans 
from pathogenic infection by microorganisms, it is natural to question its apparent 
failure to control cancer. It is commonly ascribed to the lack of evolutionary pressure 
to prevent or battle cancer in older age[8]. If so, then the goal of immunotherapy is 
to understand this natural failure and intervene to access the potential power of anti-
cancer immune responses.  
 
With added knowledge of the immune response to pathogenic microorganisms, 
aberrant responses to self-tissues and tolerance to self-tissue from these robust 
categorical pathologies and homeostatic tolerance to self, evolutionarily formed, 
consistent mechanistic knowledge can be gained. Experimentally and clinically, the 
therapeutic potential of these cells is harnessed through multiple therapeutic 
strategies, most of which rely on cytotoxic T cells for proximal killing of tumor cells. 
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Cytotoxic T Lymphocytes 
Cytotoxic T lymphocytes are derived from precursor cells that originate in the bone 
marrow, mature in the thymus and, by expressing CD8, recognize MHC Class I 
bound peptides via T cell receptors (TCR). As such, this cell can recognize peptides 
generated inside cells. The TCR is composed of an alpha and a beta chain and 
functions in a super-complex with CD3 family members, CD8 and a wide variety of 
accessory molecules that integrate information in the context of TCR ligation to 
MHC Class I.  
 
The TCR beta chain is composed of three genetic components, the Variable, 
Junctional and Diversity regions. Through recombination and end-joining deletions 
and additions, a high-order of diversity is generated in the somatic germline DNA. 
Limited rearrangement of Variable and Junctional regions occurs in the much more 
stable alpha chain. These proteins pair to form a unique TCR in each T cell during 
development in the thymus. In the thymus, the majority of T cells that cannot 
recognize MHC Class I are destroyed, and subsequently those that remain that bind 
too well are destroyed. These two processes are termed “Positive and Negative 
Selection” and precede the appearance of CTLs in any immunological process. The 
peptides presented in the thymus represent translated coding regions of human 
DNA; thus, by this process, auto-reactive T cells are destroyed (self), and TCR of 
unknown peptide specificity (non-self) survive to enter the body. The removal of 
self-reactive T cells in the thymus is known as “Central Tolerance”. The TCR 
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repertoire of T cells, which emerge from the thymus, constitutes the range of 
specificity that can be utilized to detect infected or aberrant cells in the body. These 
T cells can be primed by Dendritic cells in the lymph nodes or the periphery prior to 
migration to the tumor site. Though antigen presentation by non hematopoietic cells 
can tolerize CTLs in the absence of appropriate costimulation[9]. In the case of 
tumor reactive Til, it is presumed that priming has occurred early in the natural 
history of carcinogenesis[10]. Thus, the effector phase of the immune response is of 
proximal importance.  
 
Upon ligation of its TCR, primed melanoma Til have the potential to kill the tumor 
cell. The two most studied mechanisms are perforin/granzyme-based killing and 
FAS-FAS Ligand killing[11,12]. By forming an immunological synapse with the 
tumor cell, CTL exocytose vesicles containing perforin and granzyme are deposited 
proximal to the tumor cells and form pores to access the target cell’s intracellular 
space, where serine protease activity, triggers caspase dependent apoptosis[12].  
 
The importance of effector T cell function in melanoma immunotherapy is 
highlighted by the local functional tolerance of melanoma-reactive T cells in the 
tumor site relative to those circulating in the blood[13]. Stimulation of these tolerized 
cells reveals defects in the release of perforin and granzyme[14]. In murine models 
of both spontaneous and carcinogen induced (MCA) cancer, Perforin knockout mice 
are more susceptible to tumor formation, and B cell lymphomas [15,16,17]. 
Cytotoxic T lymphocytes were further shown to be the mediator of tumor rejection 
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sensitive to the loss of perforin in these models[16]. Based on these data, clinical 
populations were screened and germline Perforin and Fas deficiencies are 
observed in some lymphoma patients[18]. 
 
FASL mediated killing traces a similar pathway as perforin and granzyme, requiring 
caspase activation, and leading to the death of FAS expressing melanoma cells. 
However, this mechanism of target killing is less important in isolation than perforin 
in controlled genetic animal studies where FAS deficient tumors were compared 
with normal tumor cells[17].   
 
The expression of dominant negative receptors for IFN-γ on tumors cells has a 
significant effect on tumor immunogenicity, and implantation experiments verify that 
CD8 mediated immunity is blunted without the direct effects on the cancer cells[19]. 
Direct anti-melanoma effects of IFN-γ, have been studied in cell lines where 
consistently, stimulation downregulated the prosurvival and differentiation protein 
MITF [20]. However, in addition to direct effects on tumor cells, IFN-γ can also 
enforce the polarization of T cells toward a function phenotype well suited for 
cellular anti-cancer immune responses. Genetic loss of IFN-γ allows for more rapid 
spontaneous tumor development. IFN-γ-/- animals (C57BL/6J, BALB/c and 
129/SvEv) develop lymphoma and epithelial malignancies at greater rates than wild-
type animals[15,21,22]. In an accelerated model of MCA induced cancer with p53 
deficiency, IFN-γ is also important in reducing the emergence of tumors[23]. 
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Antigen Presentation 
Peptides from 8-11 amino acids in length are processed in the endoplasmic 
reticulum and loaded on human cells in a process termed “antigen presentation”. 
This ongoing process results in the production of a trimolecular complex composed 
of a peptide, an MHC Class I molecule and a Beta-2-microglobulin. The continual 
production and turnover of these complexes provides a constant presentation of the 
intracellular protein content of a cell to proximal CTLs. This capability underlies the 
centrality of CTLs in the response to viral infection, intracellular bacteria and cancer. 
Through the specific recognition of unique peptides, CTLs possess the ability to 
mediate specific killing of melanoma cells.  
 
Tumor Associated Antigens 
The destruction of cancer cells by CTLs is triggered by antigen recognition. 
Melanoma cells contain a wide array of antigens that can serve as unique and 
productive ligands for TCRs. A number of different melanoma tumor antigens are 
listed in Table 1 from four categories of antigens: Mutation derived, Embryonic, 
Differentiation and Overexpressed Proteins.  
 
Detailed evaluation of the specificity of melanoma Til have uncovered a wide array 
of antigens derived from mutated proteins. An example of this approach is utilizes 
melanoma biopsies where melanoma cancer lines, and Til lines can be expanded in 
vitro.. Cloning of tumor cDNA allows for the selection of Til reactive gene products 
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and isolation of specific antigens. This approach was used to successfully identify 
the neoantigen derived from a point mutation in myosin class I gene[24]. 
 
Although immune evasion can occur through the loss of antigen presentation to 
CTLs by the melanoma cells, what is most often observed is the presence of tumor 
reactive Til that are actively suppressed, mediated by melanoma cells in 
collaboration with stromal elements of the tumor microenvironment. These two 
mechanisms by which melanoma can avoid destruction by Til are not mutually 
exclusive, but rather are progressive and dynamic. The current most effective 
theory that encompasses this dynamic process is the “Immunoediting theory” 
[25,26,27]. 
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Table 1 Melanoma Tumor Associated Antigens 
 
Representative MHC Class I associated epitopes demonstrated to be of functional 
relevant in human melanoma. Category, gene name, HLA allele specificity, peptide 
sequence, and references study are included.   
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Category Gene Mutation HLA Peptide Reference 
Mutation derived Beta-catenin T37F A24 SYLDSGIHF [28] 
  N-Ras Q61R A01 ILDTAGREEY [29] 
Embryonic  MAGE-3 NA A01 EVDPTGHSY [30] 
  LAGE-1 NA A02 SLLMWITQC [31] 
Differentiation MART-1 NA A02 EAAGIGILTV [32] 
  TRP-2 NA A68 EVISCKLIKR [33] 
Overexpressed hTERT NA A0201 ILAKFLHWL [34] 
  MELOE-1 NA A02 TLNDECWPA [35] 
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Immune Evasion 
Of equal importance in the design of immunotherapeutic strategies are knowledge 
of the cancer cell, its physiology and its biological potential. The mutagenic nature 
of cancer cells allow for the development of variants within a complex field of 
selective pressures. Immune evasion refers to alterations to the cancer cell which 
obscure its specific immunogenic antigens from the adaptive immune systems. 
Many defects in the antigen presentation pathway have been discovered in 
melanoma and other cancers. Nonsense mutations and loss of functions mutations 
in HLA molecules, antigenic peptides, TAP, Tapasin, Calreticulin, ERp57, B2M and 
LMPs are the most common.  
 
Signaling changes that are secondary to specific oncogenic proto-oncogenes or 
tumor suppressor pathway loss can also downregulate components of this 
machinery. Downregulation can obtain the same effect: evasion of antigen 
recognition by Til. However, the specific mutations that underlie these defects in 
antigen presentation are poorly understood. Yet, stimulation through the IFN-γ 
receptor can upregulate the antigen presentation machinery and restore tumor 
immunity in many cases. The presence of IFN-γ secreting CTLs can in fact reverse 
the adaptation of tumors to evade detection, highlighting the logic in clinical 
intervention at the stage of immune activation. However, the overall effect of these 
approaches could still be improved. Other barriers to immunological therapy still 
exist.  
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Immunosuppression 
The presence of Til predict survival in advanced resected melanoma[36] and in the 
vertical growth phase of primary melanoma, ovarian and colon cancer CD8+ T cell 
infiltrates are also a prognostic factor[37,38]. From these observation it is fair to 
believe that suppressed Til do in fact have some anti tumor activity. Anti-tumor 
activity which could be unleashed if inhibitory mechanism were blocked[39].  
 
Several human and animal studies have provided evidence that a major barrier to 
the success of immunotherapy is multiple mechanisms of pre-existing, localized, 
tumor-induced immune suppression [40,41]. Many of these mechanisms cause 
downregulation or inhibition of T cell function and are common to multiple cancers, 
their presence frequently associated with poor patient prognosis [42]. T cell 
suppression can be manifested directly by tumor cells themselves, either through 
the secretion of inhibitory cytokines such as IL-10, TGF-β or VEGF, or through 
membrane expression of co-inhibitory molecules such as the PD-1 ligands PD-L1 or 
PD-L2 [43]. Alternatively, tumors can secrete factors that serve to recruit and 
activate inhibitory immune cells such as regulatory T cells, myeloid-derived 
suppressor cells or tumor-associated macrophages, which can in turn inhibit the 
function of TIL [44]. Despite the profound suppression of Til in the tumor, the 
presence of Til is nevertheless beneficial in the control of tumor growth[45]. 
Numerous mechanisms of CTL suppression have been uncovered which extend 
beyond the scope of this thesis. I will elaborate on only a limited number of 
mechanisms of central importance to this thesis. 
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CoInhibitory molecules 
T cell Receptor binding is a dangerous event in humans, as the outcome can be 
severe tissue damage, possibly life threatening (i.e. Graft-vs-Host Disease, 
autoimmunity)[46]. Binding cognate peptide in the context of MHC is tightly 
regulated through the integrations of hundreds of molecules in a dynamic focal 
synapse between T cells and antigen presenting cells. Interesting antigen-
presenting cells in the field of immunosuppression exists within the tumor 
microenvironment. Melanoma cells are altered-self, so unlike pathogen infected 
cells.  
 
PD-1 
The immune system is well adapted to encounter intracellular pathogens and 
mediate successful clearance. However, chronic infections have orchestrated a 
successful evasion of the immune response. One useful model useful for 
distinguishing functional differences between acute and chronic infections is the 
Armstrong (acute) and clone 13 (chronic) strains of murine LCMV. In the 
examination of immune failure against clone 13 infection, investigators in Rafi 
Ahmed’s lab observed that expression of the receptor PD-1 was stably expressed 
on antigen specific CTLs. PD-1 binds the ligands PD-L1 and PD-L2, which are 
differentially regulated during the immune response. Binding to ligand triggers the 
recruitment and activation of the SHP-1 and SHP-2 tyrosine phosphatase, 
consistent with a role in dampening TCR signaling. The blockade of PD-1, or PD-L1 
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is sufficient to restore immunity in the clone 13 infection and clear the viral infection 
and the PD-1+ dysfunctional CTLs are termed “Exhausted”.  
 
Close observation of the PD-1 and PD-L1 knock out mice show mild autoimmune 
disease. Subsequent experiments in tumor immunity models (B16)[47], (P815)[48], 
(SCCVII)[49] found that the Til typically expressed PD-1, and the blockade of the 
receptor or its ligand can restore anti-tumor function. Investigation of the effect of 
PD-1 on islet specific CTLs at the cellular level have shown by intravital microscopy 
that PD-1+ tolerized CTLs in lymph nodes fail to engage antigen in the presence of 
tissue PDL1. Even in a model of autoimmunity, where potentially reactive CTL 
reside in immunostimulatory lymphonodes, PDL1 on non hematopoetic cell can 
maintain tolerance to self. Melanoma antigen specific Til express PD-1 in circulation 
and the tumor microenvironment[50]. Thus methods to interfere with local PD-1 
ligands could have a dramatic clinical impact. Clinical trials are underway with 
antagonistic antibodies to PD-1 and PD-L1, and early results are encouraging in 
melanoma, leukemia, renal cell carcinoma and lung cancer[48,51,52]. 
 
CTLA-4 
Very much like PD-1, T cells express CTLA-4 as a checkpoint in the activation 
progress after T cell receptor ligation. However, CTLA-4 is distinctive in that its role 
appears to be more transient that PD-1, in that its expression is not stable, but 
rather maximal early after TCR stimulation. CTLA-4 competes for receptor binding 
with a critical costimulatory molecule CD28[53]. Both receptors bind CD80 and 
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CD86 with slightly different affinity[54,55].  
 
When CTLA-4 binds its ligand, it activates of the SHP-1 and SHP-2 tyrosine 
phosphatases, consistent with a role in dampening TCR signaling, like PD-1. 
Additionally, CTLA-4 can also bind the phosphatase PP2A which has a greater 
activity dampening the Pi3K/AKT pathway[56]. The CTLA-4 knockout mouse has a 
profound autoimmune phenotype, consistent with its role as an inhibitory T cell 
checkpoint. Blockade of CTLA-4 effectively treats tumors in several disease models. 
Interestingly blockade of both PD-1 and CTLA-4 increase immune rejection of 
melanoma cell in the common B16 model[57].  
 
Antibody blockade of CTLA-4 was approved for use in metastatic melanoma as a 
single agent therapy named Ipilimumab [58,59,60]. Clinical trial in advanced 
melanoma patients demonstrated an overall survival advantage with Ipilimumab 
compared to dacarbazine[58]. Interestingly Ipilimumab has serious immune related 
adverse effects that correlate with clinical activity[61]. These reactions typically are 
specific for pigmented antigens typified by vitiligo, providing in fact a unambiguous 
biomarker of drug efficacy. 
 
Microenvironment 
Melanoma typically develops in the skin prior to metastasis through the lymph 
nodes and spread the rest of the body. The microenvironment of a melanoma 
metastasis can be embedded in any tissue of the body. However, certain cellular 
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elements of the microenvironment appear to site independent. Migratory immune 
cells can infiltrate metastatic tumors at any location in the body. So too are blood 
vessels endothelial cells required and accompanying tumor associated fibroblasts 
(TAF). Cells in the microenvironment with the exclusion of the cancer cells them 
selves will be referred to as stromal cells or stromal elements in the thesis. 
 
Discerning the relationship between cells in the tumor microenvironment is a 
challenge in murine models of cancer. Transplanted tumors grow too quickly and 
spontaneous models with predictable metastasis are not available, or infeasible. 
Therefore efforts to delineate relationships between immune cells and stromal 
elements are more fractured. However, details of the effects of the stromal elements 
on tumor growth and immune response have been reported in the last decade. Most 
important are the effects of T cells, as have been discussed, and myeloid cell types, 
which appear to have an altogether protumorgenic, suppressive effect on T cells. 
Another important but less studied stromal element is the TAF. These mesenchymal 
lineage cells have been ascribed functions in chemoresistance, metastasis and 
immunomodulation. 
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Mutation based therapy 
The ultimate realization of molecular cancer medicine is the generation of effective 
agents that can specifically target cancer cells and that have little to no effect on 
normal healthy human cells. Small molecules that are structurally designed or 
discovered with specificity for functionally active mutated proteins are a class of 
agents currently being developed for clinical use. Few have been successfully 
generated, in part due to the physical limitations of the chemical space. With the 
adoption of massively parallel sequencing technologies the set of mutated genes 
and their respective proteins in cancer cells is expanding rapidly. The dramatic 
increase in targetable proteins and the ranking of these targets by prevalence will 
continue to spur efforts to generate these specialized compounds as therapeutic 
agents. 
 
In melanoma several distinct mutations are commonly observed in two major 
pathways MEK/MAPK and PI3K/AKT (Figure 2). 
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Figure 2 Melanoma Signaling Schematic Diagram 
 
Melanoma have activating mutations in genes whose protein products signal 
through the MEK/MAPK pathway. Additional mutations, of regulator gene losses 
occurs in order to activat the PI3K/AKT Pathway. On the vertical axis of this 
illustration are the histological stages of melnaoma progression. 
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MEK/MAPK Signaling Pathway 
The MEK/MAPK signaling pathway is activated by numerous canonical receptor 
tyrosine kinase (RTK) growth factor receptors. As illustrated in Figure 3, upon 
binding with ligand, RTKs dimerize, uniting the cytoplasmic tail signaling domains. 
The tail signaling domain autophosphorylate and cause recruitment and activation 
of various adaptor-signaling proteins, such as GRB2. The GRB2 associates with 
RTK domain through its SH2 domain, the SH3 domain of GRB2, binds SOS. RAS 
activation is regulated by the balance of Guanine-nucleotide-exchange factor (GEF) 
activity, SOS and inhibitory GTPase-activating protein (GAP) activity, not shown. 
Ultimately, SOS initiates the MEK/MAPK pathway by activating a membrane-bound 
RAS family member (N-RAS, H-RAS, K-RAS, RAP, RAL RHEB, RIN or RIT). Figure 
3 illustrates the position of GRP2, SOS and RAS upstream of a phosphorylation 
cascade of RAF, MEK and ERK. Three RAF family members mediate signaling in 
human cells, A-RAF, BRAF and C-RAF. Upon phosphorylation of ERK1/2, this 
protein moves into the nucleus and activates specific transcription factors.  
 
The outcome of MEK/MAPK signaling is usually cell proliferation, cell activation or 
cellular senescence. However, the ultimate effect of the activation of this pathway is 
highly context dependent, as the state of cellular differentiation and integration of 
other pathways makes outcomes of MEK/MAPK signaling unpredictable[62]. 
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Figure 3 MEK/MAPK Signaling Pathway 
 
Illustration of the key mediators of the MEK/MAPK signalling pathway originating 
from growth factor dimerization. This pathway ultimatly activates a large set of  
transcription factors which alter cell function.
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BRAF 
Most melanomas harbor mutations that result in the constitutive activation of the 
Mitogen-Activated Protein (MAPK) pathway. The appearance of one of these 
MEK/MAPK activating mutations preclude the appearance of another. The mutual 
exclusivity of these common activators of the MEK/MAPK pathway suggests 
functional redundancy. 
 
These mutations have been identified in proximal growth factor receptors and 
downstream signaling components. In melanoma activating mutations in the RTK, 
c-Kit, are frequently observed in mucosal melanomas. Mutations in N-RAS are 
commonly observed in cutaneous melanoma associated with chronic UV exposure 
(~15-30%). This mutation has the potential to activate both the MEK/MAPK pathway 
and the PI3K/AKT pathway. Embedded in the MEK/MAPK phosphorylation 
cascade, the BRAF kinase has activating mutations in 45-50% of human cutaneous 
melanomas, the vast majority of which result in a substitution of the valine at amino 
acid position 600 with glutamic acid, termed V600E [63,64]. This mutation, also 
found to a lesser extent in thyroid, colorectal, ovarian and lung tumors, results in 
constitutive activation of the MAPK pathway with efficiency at least 2 logs higher 
than that of wild-type BRAF [65].  
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BRAF is an 84.4 kD protein, encoded by a gene located on Chromosome 7q34. 
BRAF has three conserved domains, CR1, CR2 and CR3 as depicted in Figure 4. 
CR1 and CR2 regulate the binding to target proteins. CR3 is the catalytic domain 
responsible for phosphorylation of MEK. The BRAF(V600E) mutation in CR3 
enhances the kinase activity. 
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Figure 4 Distribution of BRAF mutations in cancer 
 
The x-axis of this plot represents the amino acid sequence of the human BRAF 
kinase. Schematic illustration below the axis identifies the corresponding conserved 
regions (CR) to the linear position of amino acids. Plotted on this histogram are the 
individual tumor samples (18057) in which BRAF mutations have been observed of 
a total of 92174 samples (COSMIC database)[66]. The high bias toward mutations 
at the 600th amino acid is evident[66]. 
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BRAF(V600E) Signaling   
In the physiological setting, BRAF(V600) mutations can be found in benign nevi as 
well as in melanoma. In nevi and melanoma, perhaps surprisingly, the 
BRAF(V600E) mutation is not associated with increased levels of pERK1/2 in situ, 
nor is the expression of activating N-RAS mutated proteins [67,68,69]. The signaling 
alterations incurred by the BRAF(V600E) mutation have been investigated, and thus 
numerous elements of its signaling complexity have been suggested by in vitro 
experiments.  
 
In vitro experiment with BRAF(V600E+) melanoma cells lines definitely and reliably 
demonstrate the presence and relevance of MEK/MAPK signaling pathway. 
However, additional roles for BRAF(V600E) have been postulated based on results 
using RNA interference methodologies or BRAF(V600E) specific inhibitors in 
melanoma cell lines. Liu et.al demonstrated that NFkB activity is induced by 
BRAF(V600E)[70]. Estrada et.al. demonstrate a role for BRAF(V600E) in enhancing 
signaling through p38 MAPK pathway activating JNK [71]. BRAF(V600E) has also 
been shown to be responsible for the transcription of ERK3, potentiating another 
alternate MAPK pathway [72]. However, several components of other signaling 
pathways are unaffected by BRAF(V600E): Nore1[73], 3pK[74], ID1[75], IGF1R[76], 
IGF1[77], MC1R[78], Notch[79], and methylation[80]. 
 
In an effective proteomic study, Old et.al, utilizing MEK inhibition in a 
BRAF(V600E+) melanoma cell line identified dozens of targets of phosphorylation. 
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In this screen, the protein MINERVA/FAM129B was demonstrated to be a 
downstream target of BRAF(V600E) mediated MEK activation. Previously 
uncharacterized, the authors demonstrated that MINERVA/FAM129B is required for 
successful cell invasion through collagen. 
 
Functions of BRAF(V600E) in Melanoma 
Considering Hanahan and Wienberg’s original conception of the six requirements 
for cancer, research testing the function of the BRAF(V600E) mutation has 
demonstrated roles for this mutation in several distinct cancer functional 
phenotypes[81]. 
 
Self-sufficiency in growth signal: As the major pathway transducing signals though 
growth factor receptors it is not surprising that BRAF(V600E) knockdown, specific 
inhibition or MEK inhibition blunts the proliferation of melanoma. The role for 
BRAF(V600E) has been establish through single cell and well based tumor growth 
assays in a number of reports [82,83,84,85,86,87,88,89,90]. Furthermore, growth 
inhibition BRAF(V600E) signaling interference is confirmed in experiments detecting 
cell cycle progression [91,92,93]. However, BRAF(V600E) signaling inhibition can 
result in either G2 cycle arrest[94])[95] or G1 arrest[96,97,98,99,100].  
 
Insensitivity to anti-growth signal: BRAF(V600E) inhibition can lead to growth arrest, 
for which extraneous growth factors can dominantly rescue [101]. The mechanisms 
of growth arrest may differentiate the functional role of BRAF(V600E). In melanoma 
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cell lines, growth arrest through two mechanisms rely on BRAF(V600E), metabolic 
stress [82,85] and anchorage independent growth [82,97,102,103]. 
 
Angiogenesis: In a model of melanoma xenografts, the BRAF(V600E) signaling 
pathway was essential for proper vascularization of the tumor and subsequent 
tumor growth [86]. Important for the process of angiogenesis, BRAF(V600E) 
regulates survival in Hypoxia by upregulating HIF1alpha [104] and transcriptional 
upregulation VEGF [105]. 
 
Tissue Invasion & metastasis: Multiple experimental methodologies in use attempt 
to isolate distinct cellular actions required for tissue invasion and migration, required 
for metastasis. In the absence of BRAF(V600E)-induced MEK/MAPK signaling, 
melanoma cells have reduced capacity for matrigel Invasion 
[83,84,106,107,108,109], metastatic extravasation in vivo [110,111], transformation 
in soft agar [63,87,108,112], and acquisition of 3D invasion ability through collagen 
matrix [113,114]. In all these systems, BRAF was important for metastatic behavior.  
 
Resistance to apoptosis Crucial for the progression of melanoma is the resistance 
to apoptosis. A general dependence of melanoma cell lines on BRAF(V600E) to 
prevent spontaneous apoptosis, is illustrated by the dearth of studies reporting such 
evidence [70,87,90,115,116,117,118,119]. Various mechanism of apoptosis 
induction can occur in melanoma cell lines, but anoikis induced apoptosis appears 
to reproducibly depend on BRAF(V600E) signaling [116,120,121,122]. Resistance 
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to apoptosis further is shown to rely on the expression of HSP70 and HSP90 [123] 
by melanoma, and the BRAF(V600E) pathway is known to inhibit expression of the 
proapoptotic protein Bim [124].  
 
The wide variety of functions that the BRAF(V600E) mutation facilitates in the 
presently indexed studies suggests that this mutation serves multiple roles in 
melanoma progression. The reliance on the MEK/MAPK signaling pathway for 
mutant BRAF provides an opportunity to circumvent its many cellular functions with 
therapeutic intervention, but with obvious caveats. The presence of the mutation 
alone fails to predict specific functional dependency upon the activated pathway. 
Therefore understanding the requirements put on this pathway in patients or even 
during progression in rodent models of BRAF(V600E)+ melanoma is unreliable.  
 
Three murine models of melanoma have been developed that utilize the 
BRAF(V600E) mutation[125,126,127]. Although spontaneous, UV and chemically 
induced murine cancers, including melanoma fail to generate BRAF(V600E) 
mutation, the controlled expression of this mutated oncoprotein is function in vivo. 
Summarily, these models by Bosenberg, Haluska and Marais, all generate 
melanomas with different penetrance after initially recapitulating the senescent 
phenotype of BRAF(V600E)+ nevi. Further work with these models is needed to 
understand the nature of BRAF(V600E) during the earliest stages of immune 
surveillance.  
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Figure 5 Chemical structure of Vemurafenib and Responding Patient 
 
Vemurafenib was developed based on crystallographic modeling techniques to 
have selective binding to BRAF(V600E) kinase domain. The agent is a potent 
inhibitor of the BRAF(V600E) kinase. Scans of melanoma tumor glucose 
metabolism after 2 weeks of daily administration of Vemurafenib. Heavy tumor 
burden in the lower extremity is highly responsive to Vemurafenib at the metabolic 
level.  Lower figure reproduced with permission of copywrite holder. [128] 
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Clinical experience with BRAF(V600E) inhibitors 
The preponderance of data suggests an important role for mutant BRAF signaling 
through the MEK/MAPK signaling pathway in most melanoma, however previous 
clinical experience with RAF inhibition was disappointing. Sorafenib (BAY 43-9006) 
is a BRAF inhibitor that failed in phase II trial in advanced melanoma, despite 
success and approval for hepatocellular and renal cell carcinoma[129]. However, 
several agents under development are currently in testing to better attack this 
crucial pathway. The first such agent to receive FDA approval is 
Vemurafenib[128,130]. The oral daily dosing with this drug at 960 mg twice per day 
can achieve an 48% response rate.  
The overall experience with the remarkable success of Vemurafenib highlight the 
failure of single agent treatment approaches for melanoma. 
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Rationale for combination therapy 
The successful implementation of immunotherapeutic approaches in melanoma, 
and the recent advance in targeted inhibition of the BRAF(V600E) mutation avail an 
opportunity for combination therapies. However, the rational implementation of this 
drug with the relatively wide varieties of immunotherapy available and with proper 
consideration for patient selection requires significant understanding of the role of 
this mutation in the suppression of the anti tumor immune response. There is a 
great opportunity to serve melanoma patients by developing a knowledge base that 
can reveal complimentary therapeutic opportunities.  
 
Work by Kawakami established a role for BRAF(V600E) in the secretion of IL-10, IL-
6 and VEGF in some melanoma cell lines[105]. These cytokines regulate the 
priming ability of dendritic cells, and the loss of BRAF(V600E) signaling can 
diminish their production levels, thus allowing dendritic cells to better prime anti 
tumor T cell responses.  This observation is especially interesting due to the 
metastatic pattern of melanoma through the lymphatic system. It is possible that 
poor priming results from the presence BRAF(V600E) induced cytokines in the local 
priming organ. However, this would be most clinically relevant upon immediate 
detection of primary lesions where the immune response is still nascent. Even 
though the priming of T cells toward tumor antigens will occurs prior to metastatic 
disease, primary melanoma lesions commonly contain tumor reactive Til. 
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Prior to the discovery of BRAF(V600E) it was known that MAPK/MEK inhibition 
increases MAA: Mart-1, gp100, Tyr and TRP1[131,132]. Therefore it was not 
surprising when Boni et. al. reported that inhibition of BRAF(V600E) and MEK 
inhibition of melanoma cells could upregulate this class of tumor antigen[133]. 
Increased antigen correlated with more CTL recognition and killing in vitro. This 
data suggests that BRAF(V600E) inhibition can assist in antigen recognition by Til 
in the tumor microenvironment. 
 
In line with these studies, I extend research in this thesis on the role of 
BRAF(V600E) regulated cytokines on melanoma tumor associated fibroblasts (TAF) 
in the tumor microenvironment. I operate under the hypothesis that the 
BRAF(V600E) mutation is a critical regulator of T cell immune suppression in the 
melanoma microenvironment.  
 
In doing so, I determined for the first time that IL-1 a and IL-1 b are regulated by the 
BRAF(V600E) mutation in melanoma cells. I further determined that in collaboration 
with IL-1 activated TAFs, BRAF(V600E) can suppress Til via PD-1 and 
Prostaglandin E2. This is the first evidence for BRAF(V600E)-mediated regulation of 
PD-1 ligands in the melanoma microenvironment, and I demonstrate the treatment 
of melanoma cells with the drug Vemurafenib blocks this mechanism of 
immunosuppression. 
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Chapter 2 
 
BRAF(V600E) as a regulator of immunomodulatory molecules in 
melanocytic cells 
 
Introduction 
Immunosuppression in the tumor microenvironment is categorically different from 
tolerogenic tissue homeostasis. In normal tissues, the peripheral tolerance is 
maintained by a variety of mechanisms that are disregulated in autoimmune states. 
However, even in autoimmune states when disregulation is occurring, the 
interactions between cells and within cells are governed by normal germline-
encoded molecular programs. In otherwise immunologically normal individuals, this 
disregulation is cellular and molecular but does not involve novel molecular entities. 
In the tumor, microenvironment novel molecular entities alter the operating rules of 
the tissues providing for an explicitly unnatural deviation from normal tissue level 
regulation of the environment. The tumor cell can break “the rules”. 
 
The direct or indirect regulation of immune-related molecules by cancer cells may 
be mediated by several distinct mutations of obvious importance. This includes the 
loss of melanoma-associated antigen expression, which permits the evasion from 
direct killing by cognate cytotoxic T cells frequently found in melanoma lesions. A 
functionally equivalent mutation in B2M or HLA molecules can exact the same 
outcome, as can the loss of critical antigen presenting machinery such as TAP1, 
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TAP2, Tapasin, ERP1 or calreticulin. Indirectly, a tumor cell may increase the 
production of a secreted factor, which has a suppressive effect upon cytotoxic T 
cells at higher concentrations. TGF-β and IL-10 are the major examples of these 
secreted factors. Cytotoxic T cells with the relevant receptors for these factors will 
have reduced responses to cognate antigens. However, unlike the loss of function 
mutations leading to immune evasion, the mechanism by which a cancer cell 
achieves an immunosuppressive microenvironment is not known. Yet, control of 
tumor growth by the immune system can be impaired by either class of interactions 
or, by logical extension, local intermediary cells can integrate signals from the 
tumor-secreted factors and collaborate in the generation of a suppressive 
microenvironment. 
 
Enhanced expression of gene products is an anticipated outcome of activated 
oncogenic signaling pathways. Activating mutations in important signaling pathways 
bypass normal regulation and downstream transcription is enhanced. The genetic 
mutations in melanoma cells are diverse and deeply integrated at the time of 
metastasis. The integration of altered signaling required for tumor progression can 
mask the effect of a single mutations contribution to a cells phenotype. This is 
perhaps the case for BRAF(V600E). In an effort to define a genetic signature for this 
mutation, several investigators conducted transcriptional screens with melanoma 
cell lines 
[72,75,94,104,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150]. 
 
However, the presence of the common BRAF mutation in metastatic melanoma 
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cells with integrated signaling networks fails to show a predictive transcriptional 
signature. Therefore, the contribution of BRAF(V600E) to the transcription of 
immunoregulatory molecules is not determined by previous studies. One could 
suggest that the presence of BRAF(V600E) early in the etiology of melanoma 
necessarily means that its predictive signature is distorted by the adoption of 
additional mutations. As such, determining general effects of the BRAF(V600E) 
mutation on the diverse background of a number of unknown other mutations 
appears to yield data limited to individual melanoma cell lines. 
 
Results and Discussion 
BRAF(V600E) Transcriptional Screen  
 
In order to assess the downstream gene transcription profile induced by 
BRAF(V600E), I developed a lentiviral vector-based system to enforce expression 
of this oncoprotein in primary human melanocytes, thus mimicking one of the 
earliest events in melanomagenesis (Figure 6).  
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Figure 6 Oncogene Expression Vector  
 
A CMV promoter was used to drive expression of either wild-type (wt) BRAF or 
mutated BRAF(V600E), and eGFP expression driven by a downstream IRES 
element. 
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Figure 7 Ectopic expression of BRAF(V600E)  in melanocytes 
 
Flow cytometric analysis of green fluorescent protein (GFP) and BRAF expression 
in dermal melanocytes following transduction with lentiviral- expression vectors 
BRAF(wt)-IRES-GFP, BRAF(V600E)-IRES-GFP or empty-IRES-GFP. Gated 
GFP(dim) cells were sorted for use in subsequent studies.  
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As shown in Figure 7, GFP fluorescence correlated with the expression of BRAF 
protein, as determined by intracellular staining. To control for potential artifacts due 
to BRAF overexpression, GFPlo cells were collected and analyzed for changes in 
global gene expression. Cells transduced with empty vector-IRES-eGFP provided a 
mock control, and comparisons with (wt) BRAF-transduced cells provided a control 
for V600E-specific gene transcription. Using this system, I analyzed how the 
introduction of ectopic expression of BRAF(V600E) in melanocytes specifically 
upregulated the transcription of immunomodulatory genes after 36 hours (Figure 8).  
 
In addition to upregulating the expression of genes previously linked to oncogenic 
BRAF, including IL-6, IL-8, VEGF, CCL2, DUSP6 and SPRY2, BRAF(V600E) also 
significantly increased the transcription of IL-1α and IL-1β genes (Figure 8). IL-1 is a 
major inducer of inflammation in a variety of physiological settings, including fever 
and wound healing.  
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Figure 8 Human dermal melanocyte gene expression profiling  
 
Expression levels of selected genes from transduced and sorted human neonatal 
foreskin-derived dermal melanocytes (36 hours following transduction). Heatmap 
represents color-coded expression levels for each sample compared to 
untranduced controls. 
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Figure 9 Cytokine profiles in supernatants of transduced human dermal 
melanocyte preparations.  
 
Luminex assay showing cytokine profiles in supernatants of transduced dermal 
melanocyte preparations cultured for 5 days. Results are representative of 4 
independent experiments. 
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As such, I confirmed the effect of gene transcription on cytokine function secretion 
by analysis of the culture supernatants. After 5-7 days of culture, transduced 
melanocytes expressing BRAF(V600E) had released substantially more IL-1a, IL-
1b, IL-8, VEGF and MCSP but not IL-6 (Figure 9). 
 
To determine whether these results were also relevant for melanoma tumor cells, I 
performed a similar transduction of the HS294T melanoma cell line, which naturally 
expresses only (wt) BRAF. As shown in Figure 10, expression of BRAF(V600E) 
induced similarly high levels of IL-1α gene transcripts compared to HS294T cells 
transduced with (wt) BRAF or with empty vector. As might be expected, the induced 
gene expression patterns between primary melanocytes and HS294T cells showed 
partial overlap; however, the common upregulation of the IL-1α gene in both cell 
types indicated that oncogenic BRAF(V600E) may be linked to IL-1-mediated 
inflammation in melanoma.  
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Figure 10 Gene expression profiling of transduced HS294T cells 
 
Expression levels of selected genes from transduced HS294T cells (24 hours post-
transduction). Heatmap represents color-coded expression levels for each sample 
compared to untranduced controls. 
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Inhibition of BRAF(V600E) abrogates IL-1α and IL-1β production by melanoma 
cells.  
In order to test the hypothesis that BRAF(V600E) was responsible for driving IL-1 
production in melanoma, I measured production of IL-1 by BRAF(V600E)-positive 
melanoma cell lines prior to and following treatment with the BRAF(V600E)-specific 
inhibitor Vemurafenib (also known as PLX4032, RG7204, or RO5185426). As 
shown in Figure 11, Vemurafenib (1µM) treatment of the WM793p2 cell line resulted 
in a progressive reduction in both IL-1α and IL-1β mRNA transcripts, which reached 
minimum levels within 3-4 hours. Consistent with this result, Vemurafenib treatment 
reduced IL-1α to nearly undetectable levels at doses as low as 0.1 µM, as 
demonstrated by intracellular staining and flow cytometric analysis (Figure 12).  
 
In order to determine if this was a more generalized regulatory element of IL-1 
transcription on melanoma, I tested four other IL-1-producing melanoma cell lines, 
three of which were positive for V600E (A375, EB16-MEL and KUL84-MEL), and 
one which expressed (wt) BRAF (HS294T). As shown in Figure 13, only in the 
BRAF(V600E)-expressing cell lines was IL-1 production reduced in response to 
Vemurafenib treatment. This IL-1 inhibition was also confirmed using direct shRNA 
knockdown of BRAF(V600E) (Figure 16). 
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Figure 11 Inhibition of BRAF(V600E) abrogates IL-1α and IL-1β production by 
melanoma cells. 
 
RT-PCR analysis of IL1A, IL1B and GAPDH transcripts in BRAF(V600E)-positive 
WM793p2 cells at different time points following treatment with 1µM Vemurafenib. 
Expression levels were normalized to GAPDH expression and adjusted to 
corresponding baseline samples.  
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 Figure 12 Flow cytometric analysis showing intracellular IL-1β expression 
 
Flow cytometric analysis showing intracellular IL-1β expression in live cell gated 
WM793p2 cells 48 hours following treatment with titrated doses of PLX4032.  
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Figure 13 Effect of Vemurafenib on IL1A and IL1B RNA expression in 
melanoma cell lines 
 
Transcript levels of IL-1α, IL-1β and CNX in five Vemurafenib-treated melanoma cell 
lines expressing either (wt) BRAF (HS294T) or V600E-mutated BRAF (A375, EB16-
MEL, KUL84-MEL, WM793p2). Transcript levels were normalized to GAPDH 
expression and adjusted to corresponding baseline samples. Data represents 5 
experiments with WM793p2 and 3 experiments with other lines. 
 
 
 
	  59	  	  
 
 
 
  
IL1A
IL1B
CNX
0
1.0
0
1.0
0
1.0
HS
29
4T
A3
75
EB
16
-M
EL
KU
L8
4-
M
EL
W
M
79
3p
2
Baseline
1 Hour
4 Hour
BRAF wt BRAF V600E
No
rm
ali
ze
d 
Ex
pr
es
ion
 L
ev
el 
	  60	  	  
Collectively, these results demonstrated that BRAF(V600E) inhibition by 
Vemurafenib can effectively reduce IL-1 production in a V600E-positive melanoma 
cell lines at doses <100 times lower than those typically found in Vemurafenib-
treated patients (8). Because alternative pathways could be enforcing the 
production of IL-1 in melanoma cells in vivo I evaluated these in vitro finding in a 
xenograft model of melanoma using A375 cell line. Seven days after implantation of 
1 million tumor cells in the flank of a NOD/SCID mouse, animals were administered 
the Vemurafenib analogue PLX4720 by oral gavage. After 3 days of treatment 
tumors are excised for analysis. Representative H/E staining of vehicle and inhibitor 
treated tumors are shown to demonstrate the presence of tumor cells, in a fibrotic 
tumor stroma (Figure 14). 
 
Analysis of human RNA levels in tumor lysates recapitulated my in vitro finding, that 
BRAF(V600E) inhibition arrests the transcription of both IL-1a and IL-1b (Figure 15). 
Furthermore, consistent with the in vitro BRAF expression studies performed in 
melanocytes, transcription of IL-8 but not that of other control genes was also 
abrogated. This data shows that BRAF(V600E)-specific inhibitors can block the 
transcription of IL-1α, IL-1β and IL-8, thus altering the cytokine milieu within the 
melanoma tumor microenvironment. 
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Figure 14 Histopathlogy of A375 xenografts  
 
Photos showing H&E staining of representative, A375 xenograft tumor sections 
excised from NOD/SCID mice. Prior to excision, mice with established tumors were 
treated for 3 days with either PLX4720 or DMSO vehicle control. Magnification: 4x. 
.  
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Figure 15 IL1A and IL1B transcriptional suppression in vivo 
 
Human IL-1α, IL-1β, IL-8, GRO-α, PD-L1, and PD-L2 transcripts derived from 
human A375 xenografts implanted into NOD/SCID mice and treated for 3 days with 
PLX4720 or vehicle. Data shown is the average of 3 mice per group and are 
representative of 3 separate experiments. 
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Figure 16 BRAF shRNA expression correlates with loss of IL1α protien in vitro  
 
IL-1α staining in cell lines transduced with scrambled shRNA vector, BRAF 
targeting shRNA vectors or untranduced as indicated. Expression of shRNA is 
indicated by coexpression of RFP (x-axis) and is induced by treatment with 2 ug/mL 
Doxycycline (DOX) (Lower). Cells were treated with DOX for 11 days prior to 
analysis by intracellular staining for IL-1α. 
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IL-1α and IL-1β expression in human melanoma in situ 
IL-1α and IL-1β expression have long been associated with melanoma; however, 
wide discrepancies exist in reports of its prevalence as IL-1α or β positivity has 
ranged from ~10% to 70% of samples analyzed [151,152,153]. The sole ability to 
upregulate IL-1a and IL-1b RNA is insuffient to generate active IL-1. Additional 
cleavage of proform IL-1 is required. However, given the role of BRAF(V600E) 
signaling on the regulation of these cytokine’s RNA I sought to test if the 
BRAF(V600E) mutation is correlated with IL-1 production in patient melanoma 
samples. 
 
First, using a tissue array generated to represent melanoma different stages of 
development from a nevus, primary and metastases, I evaluated the frequency of 
positive staining for IL-1α and IL-1β (Figure 17). Analysis showed that IL-1α is 
expressed at all stages of melanoma and in benign nevi at a frequency ranging from 
63 to 88%, whereas IL-1β is expressed at a lower overall frequency in melanoma 
(13 to 20%) and not at all in nevi (Table 2). Mutation data is not available for tumors 
represented on this array, so correlation analysis was not possible, but the 
frequency of IL-1 expression is greater than that of the BRAF(V600E) mutation, 
suggesting that other elements could drive the expression of IL-1 in melanoma.  
 
Patient samples with known BRAF mutations were acquired and assembled into 
additional tissue arrays to directly test if IL-1 is associated with the BRAF(V600E) 
mutation. However, limited samples prevented a fully powered study, I observed the 
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presence of IL-1 expression was associated with tumors harboring BRAF(V600E) 
mutations. Patient tumors with (wt) BRAF express IL-1α and IL-1β both broadly in 
tumor cells and intensely (Figure 18). This is consistent with the presence of IL-1 
expression by melanoma cell lines grown in vitro which have (wt) BRAF and also 
express IL-1. 
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Figure 17 Range of IL-1α and IL-1β staining in Melanoma 
 
Sections of a melanoma progression tissue array stained with antibodies specific for 
IL-1α or IL-1β and visualized by Vector-red immunostaining. Red color indicates 
positive staining for (C-E) IL-1α or (G-I) IL-1β in representative primary and 
metastatic tumors.   
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Table 2 Prevalence of IL-1α and IL-1β in melanoma 
Frequencies of IL-1α and IL-1β staining at different disease stages. 
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Melanocytic Lesion IL-1 ? IL-1 ? 
Nevus  22/35 (.63) 0/35 (.00)
Primary 50/57 (.88) 10/49 (.20)
Metastasis 44/55 (.80) 7/55 (.13)
?????????????????????????????????????????
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Figure 18 Relationship of BRAF(V600E) mutation and IL-1α or IL-1β levels in 
situ 
 
IL-1α or IL-1β from stage 3 lymph node metastasis of tumors with (red) or without 
(black) the BRAF(V600E) mutation. Scores indicates the product of the intensity of 
signal (0-3) and frequency (0-100) of immunoreactive cells.   
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The expression of IL-1 in melanoma tumors lacking the BRAF(V600E) mutation 
suggests that alternative mechanisms of MAPK pathway activation may also induce 
its expression. Thus, oncogenic BRAF(V600E) is sufficient, but not necessary, to 
upregulate IL-1 production melanoma. 
 
In early experiments conducted to test the role of BRAF(V600E) expression on T 
cells suppressive molecules, dermal fibroblasts were treated with culture 
supernatants as analyzed in Figure 9. I observed that PD-L1 could be specifically 
regulated by the BRAF(V600E)-induced cell supernatant (Figure 19). The absence 
of IFN-g and TNF-a, as well as bacterial proteins, suggested to me that another 
soluble factor could be responsible. The strong evidence for the upregulation of IL-1 
by BRAF(V600E) in these samples led me to test the role of this cytokine on the 
expression of PD-L1 on fibroblasts. Using neutralizing antibodies with the culture 
supernatants and adding IL-1 in this preliminary experiment indicated that IL-1 was 
necessary and sufficient for the upregulation PD-L1 on these cells. With these 
preliminary results, I further attempt to understand the role of BRAF mediated IL-1 
on the fibroblast of the melanoma microenvironment, melanoma TAFs. 
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Figure 19 Regulation of PDL1 on fibroblasts by BRAFV600E transduced 
melanocytes. 
Culture supernatants from melanocytes that were stably transduced to express 
either wt or mutated BRAF and then exposed these supernatants to fibroblasts 
overnight. Flow cytometric analysis revealed that only conditioned media from 
BRAF(V600E)-transduced melanocytes, but not those transduced with (wt) BRAF or 
GFP vectors, were capable of upregulating surface expression of PD-L1 (Figure 
5A). Importantly, IL-1α/β antibody blockade abrogated this PD-L1 expression, 
demonstrating that IL-1 is the sole mediator of PD-1 ligand upregulation on TAFs 
induced by BRAF(V600E).  
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Chapter 3 
 
BRAF(V600E) regulated soluble factors signal to tumor associated 
fibroblasts 
Introduction 
In this chapter, I address the immunomodulatory role of BRAF in the tumor 
microenvironment by following up the conclusion of the previous chapter. 
BRAF(V600E) upregulates IL-1α and IL-1β transcription, and conversely, blocking 
this oncogene arrests cytokine production. Having preliminary data that IL-1 can 
regulate PD-L1 on dermal fibroblasts, I focus my attention on the fibroblasts of the 
melanoma microenvironment, melanoma TAFs. These cells have been implicated 
as immunomodulatory in cancers in vivo and in vitro. However, the role of IL-1 on 
these cells has not been described. However, in vitro culture experiments with 
NIH3T3 fibroblast cell lines and melanoma cell lines have implicated IL-1 signaling 
from melanoma to fibroblasts as a dominant factor in this setting. With access to 
surgically-removed patient metastasis, I conduct my study of these cells in the 
melanoma microenvironment with primary cells.  
 
I explored the hypothesis that IL-1 production within the melanoma tumor 
microenvironment could regulate T cells through interactions with resident stromal 
fibroblasts. In melanoma tumor samples containing TIL, lymphocytes are frequently 
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found in close proximity to phenotypic or smooth muscle actin (SMA)-a positive 
TAFs, which line tumor vasculature and form physical barriers between TIL and 
tumor cells (Figure 20).  
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Figure 20 Melanoma Tumor Associated Fibroblasts in situ 
Tissue sections from two representative melanoma metastases labeled with anti-α-
SMA antibody and visualized with peroxidase immunostaining. Red-brown color 
shows staining of α-SMA-positive tumor-associated fibroblasts (TAF), asterisks 
denote tumor cells, arrows indicate tumor infiltrating lymphocytes (TIL), and ‘V’ 
denotes tumor vasculature.  
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Results and Discussion 
 
To investigate whether fibroblasts derived from melanoma tumors demonstrated IL-
1-dependent expression of immunosuppressive molecules, TAFs were isolated from 
cultured digests of melanoma metastases by CD90 bead positive selection or FACS 
based cell sorting [154,155,156] (Figure 20).  
 
Global Transcriptional analysis of IL-1 signaling in melanoma TAFs 
 
I performed a global transcriptional analysis of TAFs treated with IL-1, with the 
primary aim of being to identify candidate immunomodulators that might mediate the 
immune modulation of T cells. For this experiment, TAFs were isolated and purified 
from three different melanoma patient tumors derived from metastases of lymph 
node, lung and soft tissue (Figure 20). The isolated TAFs were treated with IL-1α in 
culture for 24 hours, and mRNA was isolated for gene expression microarray 
analysis. The purity of CD90 selection for the discrimination of myeloid and 
endothelial cells is indicated by the high signals for CD90, a-SMA, Fibroblast 
Specific Protein (FSP), and as signals for the endothelial marker CD31, myeloid 
marker CD11b being equivalent to the T cell marker CD3 delta. 
 
IL-1α treatment induced the transcription of 197 genes with a False Discovery Rate 
(FDR) of 0.01, common to all three TAFs (Figure 21). These included a number of 
genes with immune-related functions, including multiple chemokines as well as 
several cytokines which are included in the larger sets of cytokines and chemokines 
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in Figures 23 and 24. Interestingly, many of these genes have been previously 
associated with melanoma, suggesting that IL-1 treated TAFs may act as signal 
amplifiers for melanoma-associated gene products IL-8, IL-6, IL-1α and IL-1β. 
 
Importantly, a number of upregulated genes were potential mediators of T cell 
suppression (Table 3). For conformational studies, I focused on three genes: COX-2 
and the PD-1 ligands PD-L1 and PD-L2 (Figure 21). These genes were among the 
most highly upregulated and are known to exert powerful suppressive effects on T 
cells, and their mechanisms of action have been relatively well-characterized in 
multiple cancer types [157,158]. 
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Figure 21 Cultured Melanoma TAF micrograph 
Cells isolated by CD90 expression after 1 week in culture post tumor digest. Cells 
cultured 3-5 weeks in total. Tumor-associated fibroblast (TAF) cultures were derived 
from three metastatic melanoma biopsies from three distinct anatomical sties: lymph 
node, lung and soft tissue. 
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Figure 22 Unsupervised clustering of IL-1α regulated genes in three TAFs 
derived from metastatic melanoma patients.  
 
Cultured TAFs were exposed overnight to IL-1α, and treated and untreated cells 
were subjected to Affymatrix gene expression analysis. Heatmap displays the 197 
most differentially expressed genes selected at FDR 0.01. Genes have been 
standardized at +- 2 standard deviations, with a scale of log values indicated in the 
color key. 
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Figure 23 Ad hoc analysis of TAF lineage marker 
Relative gene expression levels of Fibroblast (CD90, FAP, α-SMA), melanocytic 
lineage (Tyrosinase), T cell (CD3D), myeloid dendritic (CD11c), endothelial (CD31) 
lineage-related genes as determined by Affymetrix gene expression analysis in 
three melanoma TAF cell lines. Wide lines indicate Mean, error bars indicate 1 
SEM. 
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Figure 24 Regulation of TAF cytokines by IL-1α 
Selection of cytokine genes upregulated by three melanoma TAFs after 24 hrs in 
response to IL-1α. The t-stat indicates the level of upregulation of the probe ID 
signal in response to the cytokine treatment.   
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Figure 25 Regulation of TAF Chemokines by IL-1α 
Selection of chemokine genes upregulated by three melanoma TAFs after 24hrs in 
response to IL-1α. The t-stat indicates the level of upregulation of the probe ID 
signal in response to the cytokine treatment.   
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Table 3 List of immunosuppressive factors significantly upregulated in 
melanoma TAF in response to IL-1α 
 
Selection of immunosuppressive genes upregulated by three melanoma TAFs after 
24 hours in response to IL-1α. The t-stat indicates the level of upregulation of the 
probe ID signal in response to the cytokine treatment. 
[159,160,161,162,163,164,165,166,167].  
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Figure 26 Immunosuppressive TAF transcription common to Lung, Soft tissue 
and Lymph node metastasis  
 
Normalized relative transcriptional expression levels of COX-2, PD-L1 and PD-L2 in 
24 h IL-1α treated or untreated TAFs, as analyzed by the Affymetrix gene 
expression array   
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Confirmation of PD-1 Ligand and COX 2 induction on IL-1 treated melanoma TAFs 
 
I tested for the augmented expression of the three gene products in response to IL-
1 treatment at the protein level with multiple, independently-derived melanoma 
TAFs. Western blot analysis showed increased levels of COX-2 protein (Figure 27), 
and flow cytometric analysis demonstrated increased TAF surface expression levels 
of both PD-L1 and PD-L2 following IL-1α treatment (Figure 22 and 23). IL-1α and 
IL-1β were both shown to be very potent inducers of PD-1 ligand expression, 
demonstrating activity at concentrations as low as 1 pg/ml  and inducing protein 
expression as early as 6 hours after treatment(Figures 28 and 29). Furthermore, 
although IL-1α/β was not as effective as IFN-γ at inducing expression of PD-L1, it 
was equally effective at inducing expression of the higher affinity PD-1 ligand PD-L2 
in 9 of 9 TAFs analyzed (Figures 22). Collectively, these results demonstrate that 
TAFs exposed to low concentrations of IL-1α/β respond by rapidly stimulating the 
production of at least three molecules known to directly induce T cell suppression.  
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Figure 27 IL-1 and IFN-g induce PD-L1 and PD-L2 on melanoma TAFs 
Surface expression of PD-1 ligands PD-L1 and PD-L2 on TAFs 24 hours after 
treatment with IL-1α or IFN-γ, as determined by flow cytometry. Data from nine 
different melanoma-derived TAF lines are shown. Geometric mean fluorescent 
intensity (MFI) was determined using immuno Flow cytometry. Asterisks indicate 
statistical significance (P < 0.05); ns, not significant.  
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Figure 28 Regulation of COX-2 by IL-1 in melanoma TAFs 
Western blot analysis showing COX-2 and β-actin protein expression in four 
additional patient-derived TAF lines, prior to and 24 hours following treatment with 
IL-1α.   
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Figure 29 Phenotype similarities between Dermal Fibroblasts and melanoma 
TAFs 
Expression levels of PD-L1, PD-L2, MHC Class I and MHC Class II by normal 
human fibroblasts and melanoma TAFs after 24 hour exposure to IL-1β or IFN-γ. 
Also indicated are basal expression levels of CD90 and MCSP.   
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Figure 30 Kinetics of B7-H1 expression after IL-1 treatment 
Expression of PD-L1 on dermal fibroblasts at the indicated time after treatment with 
100 pg/mL IL-1β. Signal was measured by FACS staining.  
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Figure 31 Dose range of IL-1 regulation of PD-L1  
Expression of surface PD-L1 after 24 hours of treatment with IL-1α or IL-1β. Signal 
was measured by FACS staining. 
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Chapter 4 
Vemurafenib relieves CTL dysfunction in the presence of tumor 
associated fibroblasts 
 
Introduction 
 
Considering the importance of TIL for mediating tumor regressions in melanoma 
patients [168,169], I next tested whether cultured fibroblasts and TAFs were 
capable of suppressing CD8+ T cell function and whether IL-1 could impact this 
suppression. Further I set out to determine the contribution of IL-1 induced PD-1 
ligands on PD-1+ melanoma Til. The ready availability of COX-2 inhibitors allowed 
me also to address the contribution of the COX-2/PGE2 mechanism suggested in 
experiments from the previous chapter. 
 
Results and Discussion 
 
Interleukin-1 activated TAF mediated suppression 
 
I tested the ability of fibroblasts to suppress HLA-A*0201-restricted MART-1-specific 
CD8+ TIL in the context of direct presentation, thus in the absence of any other cell 
types to isolate the IL-1 response. Dermal fibroblasts were co-cultured with HLA-
matched, MART-1 or control dermal fibroblasts that were either untreated or pre-
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stimulated with IL-1β for 24 hours. In order to measure an integrated function of 
TCR signaling, I assessed the presence of the protein Ki-67 in the Mart-1 specific 
CTLs. Ki-67 is a protein uniquely associated with the cell cycle, being upregulated in 
G1 phase and rapidly degraded during cytokinesis[170]. Its utility in measurement of 
cycling cells is well-established in oncology and immunological fields of study.  
 
IL-1β pre-treatment reduced TIL cell cycle entry (Ki-67+ cells) by approximately 
50% in MART-1 tetramer-positive CTLs after 3 days of culture (Figure 33). Similar 
results were observed after 5 days. Thus, in the context of direct presentation of 
antigen to CTLs, IL-1 treated fibroblasts can suppress antigen induced proliferation.  
 
If this suppressive effect is mediated by altered antigen presentation, or limited to 
direct presentation, this assay was elaborated to include antigen pulsed third-party 
APCs (irradiated PD-1L- B cells). Similar results were observed in this assay, as co-
cultured IL-1β stimulated fibroblasts exerted a similarly suppressive influence on 
MART-1-specific TIL in the presence of additional antigenic stimulation from a third 
party cell (Figure 33).  
 
In order to assess the effect of fibroblasts on cytotoxic granule release I measured 
the amount of CD107 that emerges on the surface of the T cells. CD107 is a 
molecule that is typically restricted to intracellular vesicles that contain perforin and 
granzyme. However, upon fusion of these vesicles with the membrane during the 
release of the cytotoxic molecules, CD107a is transiently present on the surface of 
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the cells. Pulsing the culture media with fluorescently conjugated antibody to 
CD107a allowed me to quantify the number of cells that degranulated in response 
to the pulsed peptide, thus establishing any modulators of cytotoxic function in my 
cellular system. Although suppression could be observed with peptide pulsed cells 
with intact endogenous antigen presentation machinery, for the experiment and 
those that follow, I used a special antigen-presenting cell line known as T2. T2 cells 
lacking TAP1 and thus cannot load their MHC Class I (HLA-A201) with endogenous 
peptide. As such, pulsed cells contain only the experimental peptide, allowing more 
uniform and consistent assay conditions. 
 
As shown in Figure 32, Mart-1 containing TIL lines had increased degranulation in 
the presence of MART-1 peptide pulsed T2 cells as compared to control HIV 
derived peptides. I observed suppression of their response to MART-1 antigen in 
the presence of IL-1β pretreated fibroblasts, compared to untreated fibroblasts; 
similar results were observed with IL-1α. Suppression of proximal cytotoxic function 
is a profound defect in the melanoma microenvironment and has been ascribed as 
a function of PD-1ligation. 
 
In a third assay for CTL function, the release of IFN-γ in response to antigen 
stimulation, melanoma TAFs from 6 different patient tumors were evaluated. As 
previous described, these cells were tested for suppressive function toward MART-
1-specific TIL exposed to MART-1 peptide-pulsed T2 stimulator cells. Whereas 
untreated TAFs demonstrated some suppression of TIL cytokine production, IL-1α 
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pretreatment reduced IFN-γ production by ~5-fold (Figure 34). Furthermore, 
antibody-mediated neutralization of IL-1α/β abrogated the suppressive effect of IL-1 
in combination with TAFs (Figure 34).  
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Figure 32 Dermal Fibroblasts suppress Til cytotoxic degranulation   
Frequency of CD107a-positive MART-1 reactive TIL following co-culture with 
MART-1 peptide-pulsed dermal fibroblasts pretreated with or without IL-1α, as 
determined by flow cytometry. Data from 2 different melanoma patient TIL are 
shown, and are representative of 2 independent experiments.  
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Figure 33 IL-1α activated fibroblasts suppress Til proliferation with indirect 
antigen presentation. 
Figure 3.3 (B) Frequency of Ki67-positive MART-1 reactive TIL after 3 days of co-
culture with MART-1 peptide-pulsed HLA-A2+ dermal fibroblasts pretreated with or 
without IL-1α, as determined by flow cytometry. Data from 3 melanoma patient TIL 
are shown, and are representative of at least 5 independent experiments. IL-1 
treatment White bars, media Black bars. 
 
Frequency of Ki67-positive MART-1 reactive TIL after 3 days of co-culture with 
MART-1 peptide-pulsed antigen presenting cells (APC) consisted of third-party, 
irradiated B cells, and HLA-A2+ dermal fibroblasts pretreated with or without IL-1α, 
as determined by flow cytometry. Data from 3 melanoma patient TIL are shown, and 
are representative of at least 5 independent experiments. IL-1 treatment White bars, 
media Black bars. 
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Figure 34 IL- 1 activated melanoma TAFs suppress antigen induced release of 
IFNg by melanoma Til 
Interferon-γ release by TIL stimulated with MART-1 peptide-pulsed T2 cells in the 
presence or absence of untreated or IL-1α treated melanoma TAFs, with or without 
the addition of IL-1 neutralizing antibodies. Data are representative of six different 
TAF lines analyzed and three experimental replicates. Asterisks indicate statistical 
significance (P < 0.05); ns, not significant. 
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BRAF(V600E) inhibitor effects on melanoma activated TAF mediated suppression 
 
I next assessed whether PD-1 ligand upregulation by TAFs can be directly 
attributed to IL-1 production induced by BRAF(V600E). In order to establish this 
linkage, I first tested whether pharmacologic BRAF(V600E) inhibition could relieve 
TAF-mediated T cell suppression, I exposed six different melanoma-derived TAFs 
to supernatants from BRAF(V600E)-positive melanoma cell lines that were either 
untreated or treated with Vemurafenib. Following overnight exposure to these 
supernatants, TAFs were co-cultured with MART-1-specific TIL expressing PD-1 
(Figure 38) and MART-1 peptide pulsed T2 target cells for 18 hours. The following 
day, culture supernatants were assayed for IFN-γ production. As shown in Figure 
37, BRAF(V600E) inhibition by Vemurafenib resulted in a dramatic augmentation of 
T cell IFN-γ production in all six TAFs analyzed, supporting the notion that 
BRAF(V600E) could induce functional TIL suppression mediated through TAFs.  
 
To ascertain whether IL-1α/β, COX-2 or PD-1 ligands played a role in mediating this 
suppression, I next performed a similar experiment in the presence or absence of 
IL-1α/β or PD-L1/PD-L2 antibody blockade, or the COX-2 inhibitor NS398. Antibody 
neutralization of IL-1α/β in melanoma cell line supernatants partly relieved the 
MART-1 TIL functional suppression observed in co-cultures with TAFs (Figure 37). 
In addition, antibody neutralization of PD-1 ligands and COX-2 also partly relieved 
TAF-mediated suppression, whereas combined neutralization of IL-1α/β and PD-1 
ligands with COX-2 inhibition could further improve T cell function in two of the three 
	  122	  	  
melanoma supernatants tested. Although there was some variability in the extent of 
T cell suppression mediated by different TAF lines, overall these data are consistent 
with a role for IL-1 mediating suppression through TAFs by upregulation of PD-1 
ligands and COX-2.  
 
By contrast, neutralization of IL-1α/β in supernatants from the same melanoma cell 
lines pretreated with Vemurafenib had no significant effects on TIL function, nor did 
PD-1 ligand blockade or COX-2 inhibition facilitate increased cytokine secretion by 
T cells. These results indicate that BRAF(V600E) inhibition can relieve suppression 
of T cell function mediated by TAFs expressing PD-1 ligands and COX-2, at least in 
part through reducing IL-1α/β production by melanoma cells. Taken together, these 
experiments support a mechanism of IL-1 induced TAF-mediated immune 
suppression that is sensitive to V600E-specific inhibition.  
 
IL-1α signaling upregulates expression of immunosuppressive genes in melanoma-
derived TAFs, which results in CTL functional suppression. Understanding the basic 
mechanisms of IL-1 induced suppression by TAFs can inform more general clinical 
strategies to improve immunotherapies.   
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Figure 35 BRAF(V600E) can induce T-cell suppression through IL-1 mediated 
upregulation of PD-1 ligands and COX-2 on TAFs.  
Interferon-γ release by T2-stimulated MART-1 reactive TIL in the presence of 
melanoma patient-derived TAFs previously exposed to conditioned media from 
BRAF(V600E) mutant-expressing melanoma cell lines that were either untreated or 
treated with PLX4032. Three melanoma TAF lines were pre-treated with 
conditioned media from untreated or PLX4032-treated melanoma cell lines 
(WM793p2, EB16-MEL and KUL84-MEL), in the presence of either IL-1α/β blocking 
antibodies or the COX-2 inhibitor NS398. Pre-conditioned TAFs were then 
incubated with TIL and MART-1 peptide-pulsed T2 cells in the presence of isotype 
control antibody or antibodies specific for PD-L1 and PD-L2. P values represent 
results for paired t-tests.  
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Figure 36 Til suppression by TAFs activated by melanoma supernatants is 
releived by BRAF(V600E) inhibition 
Interferon-γ release by T2-stimulated MART-1 reactive TIL in the presence of 
melanoma patient-derived TAFs previously exposed to conditioned media from 
BRAF(V600E) mutant-expressing melanoma cell lines that were either untreated or 
treated with PLX4032. Results from five different TAF lines are shown.   
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Figure 37 Expression of PD-1 on antigen specific melanoma Til 
Flow cytometric analysis of two different TIL cultures (2159 and 2183) showing 
surface expression levels of PD-1 on total live CD8+ T cells and on MART-1 
tetramer binding CD8+ T cells. 
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Chapter 5 
 
General discussion and Future directions 
 
Discussion 
 
As a wholly embedded member of the MEK-MAPK signaling pathway, the study of 
activated BRAF, via the V600E mutation, is largely a surrogate for the study of this 
pathway as itself. However, with the unique distinction of specific inhibition with 
mutation specific small molecule inhibitors.  
 
I set out with the hypothesis that this mutation could manifest an immunomodulatory 
role in the melanoma tumor microenvironment. I observed that ectopic 
BRAF(V600E) expression in human melanocytes upregulated the expression of IL-
1α and IL-1β, I found that IL-1 production in a subset of human melanoma cell lines 
was also under the control of this same oncogenic protein. I further delineated the 
frequency of IL-1α and IL-1β production in melanoma patient samples, determining 
that the majority of tumors contain this cytokine. Additionally, I observed that the 
expression of IL-1 by melanoma does not require the BRAF(V600E) mutation. This 
set of data indicates that the BRAF(V600E) mutation is sufficient but not necessary 
of IL-1 production by melanoma. 
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As an immune modulatory cytokine with pleotropic functions, I defined IL-1α and IL-
1β signaling as regulator of immune suppression as manifested by melanoma 
tumor-associated stromal fibroblast cells (TAFs). This suppression was exerted 
upon melanoma antigen specific CTLs in part by COX-2, PD-L1 and PD-L2. In 
doing so I have delineates a novel link between oncogene activation in tumors and 
the resulting downstream effects on inflammation and immune suppression within 
the melanoma tumor microenvironment.  
  
Constitutive activation of the MAPK pathway through oncogene mutations or 
amplifications has long been recognized as a hallmark common to many different 
cancer types [171]. Such genetic lesions provide cancer cells with a number of 
distinct advantages that promote tumor growth in vivo, including increased 
proliferation, reduced apoptosis, extended survival, and augmented metastatic 
potential [70,82,86]. Examples include KRAS, found to be mutated in lung 
carcinomas, colorectal [172] and >80% of pancreatic cancers [173], as well and 
PDGFRA and CKIT, which are often mutated in hematopoetic neoplasia and GIST 
[174,175]. Although BRAF(V600E) is the most common genetic lesion in cutaneous 
melanoma, NRAS [176] is mutated in a further ~20% of cases, and CKIT and 
GNAQ/GNA11 have been shown to frequently contain activating mutations in acral 
lentiginous and uveal melanomas, respectively [177]. The frequent occurrence of 
these mutations, combined with their propensity to provide tumor cells with a 
survival advantage, has made them highly favorable targets for the development of 
therapeutic, small molecule inhibitors to fight cancer [178]. 
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Over the past decade, a number of small molecule inhibitors that target elements of 
the MAPK pathway and its downstream targets MEK and ERK have been tested in 
experimental clinical trials for cancer patients. Although these agents often show a 
high degree of efficacy in vitro or in xenogeneic animal models, clinical response 
rates have been modest. For example, therapy with a selective MAPK/extracellular 
signal-related kinase (ERK) kinase (MEK) inhibitor AZD6244 demonstrated only a 
12%-40% response rate among BRAF(V600E)-positive melanoma patients 
[179,180]. The lack of specificity of many of these drugs have often been cited as a 
major problem that not only limits their clinical efficacy, but also leads to severe off-
target effects such as cytotoxicity to immune cells that can result in lymphopenia 
and increased frequency of pathogen infections [181,182,183]. Since T cells require 
the MAPK pathway for antigen recognition and anti-tumor function, they are 
particularly sensitive to these off-target effects [184,185]. Furthermore, strong 
evidence has been accumulating that the immune system can make a critical 
contribution to antitumor responses even in the context of non-immunotherapeutic 
treatments [186,187,188,189], with the emerging paradigm being that an intact 
immune system contributes significantly to the outcome of treatment, and may be 
critical for clearance of drug-resistant tumor cells and for prevention of recurrences 
[190]. 
 
More recent generations of kinase-targeted agents have shown a much higher 
degree of specificity for the mutated forms of oncogenic kinases found only in tumor 
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cells, and importantly also show significantly less harmful effects on immune cells 
[191]. Inhibitors that specifically target mutated BRAF(V600E), such as Vemurafenib 
and GSK2118436, have shown remarkable efficacy in the clinic and in phase 
II/phase III trials, inducing responses in the majority of melanoma patients harboring 
the V600E mutation [130]. However, despite encouraging results, responses to 
BRAF(V600E) inhibition are relatively short-lived, and disease recurrence of 
inhibitor-resistant tumors occurs in nearly all treated patients [192]. These clinical 
findings have led many to propose combining BRAF(V600E) inhibition with 
immunotherapies to increase response rates, and our data suggests that this 
combination approach may show therapeutic synergy [105,191,193]. 
 
Our study identifies BRAF(V600E)-induced IL-1 as being a key mediator of immune 
suppression in melanoma. Unlike other cytokines which can impact T cells directly, 
IL-1 reinforces immune suppression indirectly through the stimulation of melanoma 
TAFs. A number of recent studies have highlighted the importance of stromal TAFs 
in promoting tumor cell survival and evasion of NK cell-mediated antitumor immunity 
[194]. Our results are experimentally consistent with these findings and show that 
IL-1α and β can induce melanoma TAFs to directly inhibit the antitumor function of 
melanoma antigen-specific CD8+ T cells. Gene expression analysis showed that 
this IL-1-mediated suppression is likely mediated by a host of factors known to 
affect T cell function as well as other lymphocytes, (Table 3), including but not 
limited to TAF expression of PD-1 ligands PD-L1 and PD-L2 and COX-2. 
Importantly, the location of TAFs within the architecture of the melanoma tumor 
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microenvironment, frequently lining tumor vasculature and/or forming a physical 
barrier between TIL and tumor cells, suggest that TAFs are ideally located to 
mediate immune cell suppression in vivo.  
 
The most crucial aspect of this study is the finding that pharmacologic inhibition of 
BRAF(V600E) in melanoma cells can relieve TAF-mediated suppression of immune 
cell function and largely restore antitumor T cell responses. Although study of a 
cohort of BRAF(V600E) inhibitor-treated patients will be required to confirm these 
findings in vivo, collectively these results have important clinical implications that 
strongly support the notion of combining BRAF(V600E)-specific inhibitors with 
immune-based therapies. In particular, it will be important to test the prediction that 
patients treated with V600E inhibitors show a reduction in tumor-mediated IL-1 
production that may be linked to reduced COX-2 or PD-1 ligand expression by TAFs 
and improved activity of tumor-specific T cells. The emerging link between MAPK 
pathway activation and immune suppression, combined with the lack of off-target 
effects shown by mutated kinase-targeted agents, suggests that such combination 
approaches may show therapeutic synergy and result in significantly better and 
more durable clinical responses in V600E-positive melanoma patients. Furthermore, 
our findings also support the notion that patients harboring non-BRAF mutated 
tumors may benefit from treatments that combine immunotherapy with IL-1 
blockade.  
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Future directions 
 
The connection of oncogenes and immunosuppressive mechanisms in the tumor 
microenvironment has the potential to guide clinical practice in the future.  The data 
collected in the progress of my work supplies several more questions calling for 
experimental validation.  The future directions I outline based on my work all follow 
the direct line of evidence generated by my work under the hypothesis that BRAF 
V600E regulates immunosuppression of the melanoma microenvironment.   
 
At the most basic level, it is important to test the effects of BRAF V600E inhibition 
on serial biopsies of patients for immunomodulatory factors including IL-1α/β, PD-
L1, PD-L2 and COX-2 both before and after treatment.  This will ascertain if in 
patients these mechanisms are robust to stand in the complex milieu of the variety 
and heterogeneous patient melanoma patient population.  Confirmation of these 
mechanisms in treated patients is strong validation of the data in this thesis. 
 
More speculatively, patient selection based on IL-1α/β level in the tumor could be a 
biomarker of those who would benefit most from combination therapy with BRAF 
V600E inhibitors and activating immunotherapies, such as high dose IL-2 or 
adoptive cellular therapy with Til or TCR modified cells.  Or, as it is a finding in this 
thesis that IL-1α/β activated melanoma TAFs increase transcription of several 
known immunosuppressive molecules at the RNA level these could serve a role as 
biomarkers.  However, it was beyond the scope of this work to determine the validity 
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of these elements in functional experiments.  But given that these gene products 
were upregulated in TAFs from different patients and metastatic sites, it suggests 
that an immunosuppressive role of IL-1 signaling in TAFs is not restricted to one 
tissue site or patient.  This weighs in favor of further efforts to understand the role of 
these molecules, perhaps as secondary indicators for patients with BRAF V600E / 
IL-1α/β axis mediated suppression of the melanoma immune response.  
 
Recently development murine models of spontaneous melanoma that are sensitive 
to BRAF V600E inhibitors offer another opportunity to evaluate the role of IL-1 
production during the early development of melanoma.  Crossing these animals with 
IL-1R1 knockout animals will be a powerful direction to further develop the finding of 
my work.  A deeper understanding of the role of sterile inflammation in the 
progression of cancer is valuable in the development of adjuvant therapies to 
prevent reoccurrences secondary to successful immunological interventions.  This 
work can only be carried out in complete physiological systems such as those 
developed in mice where immunological memory can be model.  This is far outside 
the scope of the proximal effector functions evaluated in vitro in the course of my 
work.   
 
In the process of phenotyping melanoma TAFs derived from patient biopsy material, 
it became clear to me the immunological variations at the basal level.  Although PD-
1 ligands and COX-2 are consistently upregulated with IL-1α/β treatment, other 
molecules are only induced by IFN-γ.  In fact melanoma TAFs can be bisected by 
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the ability to induce MHC Class II in response to IFN-γ.  This suggests a 
significantly different immunological role in the presence of activated T cells.  As my 
work was focused on the role of TAFs in a chronically suppressive melanoma 
microenvironment where IFN-γ is necessarily absent, and my focus was on the role 
of MHC Class I restricted CTLs this observation was not followed up.  In fact the 
diversity of immune modulatory possibility of fibroblasts is vast and future studies to 
define these in the melanoma microenvironment would be quite productive. 
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Chapter 6 
Material and Methods 
Cell Culture and Transduction 
 
WM793p2, A375 and T2 cells were cultured in RPMI 1640 medium (GIBCO Grand 
Island, NY) containing 10% fetal bovine serum (GIBCO), 10 IU/mL penicillin 
(Cellgrow Manassas, VA) and 10 mg/mL streptomycin (Cellgrow) and maintained at 
37°C in 5% CO2. The EB16-MEL and KUL84-MEL cell lines, which were kindly 
provided by Etienne De Plaen (Ludwig Institute for Cancer Research, Brussels), 
were cultured in IMDM medium (GIBCO) containing 20% fetal bovine serum 
(GIBCO), 10 IU/mL penicillin (Cellgrow) and 10 mg/mL streptomycin (Cellgrow). 
Dermal Cell preparations were obtained from Sciencell (Carlsbad, CA) and cultured 
in the provided Melanocyte Medium (Sciencell). Primary neonatal epidermal 
melanocytes were obtained from ATCC and cultured in Dermal Cell Basal Medium 
(ATCC). Patient biopsy derived TIL and TAFs were available with institutional IRB 
approval and patient informed consent. TIL or tumor digests were maintained in 
RPMI-1640 medium (GIBCO) containing 10% fetal bovine serum (GIBCO), 10 
IU/mL penicillin (Cellgrow Manassas, VA), 10ug/mL streptomycin (Cellgrow) and 
supplemented with 200 IU/mL of IL-2 (Prometheus) unless otherwise indicated 
[195]. TAFs were isolated from mixed tumor cell cultures based on CD90 positivity 
and MCSP negativity by cell sorting. TAFs were isolated from melanoma biopsies 
from lymph nodes, soft tissue, lung, brain and chest wall. 
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BRAF(V600E) and wt mutant plasmids were obtained from R. Marais [196]. Genes 
were cloned into pDonor 222 (Invitrogen) by standard methodologies. These 
constructs were then sequenced and cloned into a self-inactivating bicistronic 
lentivirus expression vector (PLV401) containing the CMV promoter via LR 
reactions (Invitrogen). Lentivirus was generated by Lipofectamine 2000 transfection 
of the packaging cell line, 293-T METR, with packaging plasmids containing 
p∆R8.91, CMV-pVSVG, and the indicated expression vectors. Viral supernatants 
were collected at 48 hours and concentrated by ultracentrifugation. Dermal cell 
preparations and Melanocytes were transduced at MOI of ~10, or by viral titration 
followed by selection of equivalently transduced lines based on GFP expression. 
Experiments using melanocytes transduced with BRAF(V600E) and control 
expression vectors were carried out between 2 and 10 days after transduction. 
 
Melanoma Xenograft  
 
NOD/SCID mice were obtained from Jackson Laboratory. Mice were maintained in 
accordance with the institutional guidelines of MD Anderson Cancer center. 
Melanoma tumors were generated by subcutaneous injection of 10 million A375 
cells on Day 0. Seven days after tumor cell inoculation, animals were treated with 
PLX4720 (100 mg/kg bodyweight), administered by gavage. This was repeated for 
two subsequent days. Vehicle solution contained 3% DMSO and 1% 
methylcellulose was used as a control treatment. Harvested tumors were divided in 
half for histology and transcriptional analysis. Experiments used 3 mice per group. 
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Reverse transcriptase polymerase chain reaction (RT-PCR)  
 
Total RNA was isolated from cultured melanoma cell lines and A375 xenografts 
using the RNAqueous NA isolation kit from Ambion. One step RT-PCR was 
conducted using iScript (Bio-RAD) according to the manufacturer’s instructions. 
Primer sequences used are as followed:  
IL1aF: 5’TGGCCCACTCCATGAAGGCTGC;  
IL1aR: 5’GTCATTGGCGATGGCGATGGCCTCCAGG;  
IL1bF: 5’GCTTATGTGCACGATGCACCTG;  
IL1bR: 5’TCCTGTCCCTGGAGGTGGAGAG;  
GAPDHF: AGAAGGCTGGGGCTCATTTG;  
GAPDHR: AGGGGCCATCCACAGTCTTC;  
CNXF: GCGTTGTGGGGCAGATGAT;  
CNXR CCGGTTGAGGTGCATCAGT.  
 
Exclusively for analysis of human transcripts from A375 xenografts, the primer 
sequences used are as follows:  
IL1aF: 5’GAGGCCATCGCCAATGACTCAGAG;  
IL1aR: 5’CAGCCGTGAGGTACTGATCATTGG;  
IL1bF: 5’GGACCTGGACCTCTGCCCTCTGGATGGCG;  
IL1bR: 5’GTACAGGTGCATCGTGCACATAAGCC;  
CXCL8F: 5’CTGCAGCTCTGTGTGAAGGTGCAG;  
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CXCL8R: 5’GGTCCAGACAGAGCTCTCTTCCATC;  
CXCL1F: 5’CGCGCTGCTCTCTCCGCCGCC;  
CXCL1R: 5’GTCCGGGGGACTTCACGTTCACAC;  
PDL1F: 5’CCACCACCACCAATTCCAAGAG;  
PDL1R: 5’CGGAAGATGAATGTCAGTGCTACACC;  
PDL2F: 5’GGACCCATCCAACTTGGCTG;  
PDL2R: 5’CACTTCCCTCTTTGTTGTGGTGACAG;  
BACTINF: 5’CGAGGCCCAGAGCAAGAGAG;  
BACTINR: 5’CGGTTGGCCTTAGGGTTCAG.  
Reactions were analyzed using a BIO-RAD CFX96 thermocycler and Ct values 
normalized to untreated samples relative to GAPDH or B-actin expression using the 
ΔΔCt method. 
 
Microarray analysis and statistical methods  
 
Transduced dermal cell preparations were sorted based on GFP expression. TAFs 
were cultured with 2 ng/mL IL-1α (PeproTech Inc. Rocky Hill, NJ) or in regular 
media for 24 hours, detached from culture plates and stored at -80 as cell pellets 
until total RNA extraction. Total RNA was extracted using RNeasy RNA extraction 
kit (Qiagen) and tested for quality by RIN analysis after product separation using an 
Agilent 2100 Bioanalyser (Santa Clara, CA). RNA was prepared and hybridized on 
Affymetrix Human Genome U133A 2.0 Array (Santa Clara, CA) by Expression 
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Analyses (Durham, NC). Expression data was normalized based on Bland-Altman 
(M-versus-A) pairwise plots, density plots, and boxplots. 
 
In TAFs, to identify differentially-expressed genes between untreated and IL-1 
treated groups, I applied modified paired two-sample t-tests using Limma package. 
The beta-uniform mixture (BUM) model, described by Pounds and Morris [197], was 
used to control false discovery rate (FDR). Heatmap displays of the 197 most 
differentially expressed genes selected at FDR 0.01 have been standardized and at 
±2 standard deviations for display purpose (The scale of the values is indicated in 
the color key). All of the tests in Figures are 1-sided t-tests, asterisks indicate p-
values of <0.05, if not explicitly provided. In some tests 1-sided t-tests are paired, 
and indicated as such. 
 
Western Blotting  
 
Cell lysates were prepared from cultured TAFs. Protein content was normalized 
using the BCA method (Thermo-Fischer Rockford, IL). Protein samples were 
separated on 10% SDS-PAGE and transferred to PVDF membrane (BIO-RAD 
Hercules, CA). Membranes were blocked in 5% nonfat milk and incubated with 
primary anti COX-2 at 1:1000 dilution overnight at 4°C. Washed membranes were 
incubated with appropriate HRP-conjugated secondary antibodies for 2 hours at RT 
prior to chemiluminescent detection (GE Healthcare, Buckinghamshire, UK). 
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Flow cytometric analyses  
 
Analysis of surface antigens on melanoma cell lines and melanocytes was carried 
out by standard flow cytometry methods. Antibodies were obtained from the 
indicated suppliers, From: PD-L1 (M1H1), PD-L2 (MIH18), AF647 labeled anti-rabbit 
IgG fabs (eBiosciences San Diego, CA); CD8 (RPA-T8), Ki-67 (B56), CD25 (M-
A251), IL-1α (AS5), IL-1β (AS10), CD90 (5E10), (BD Biosciences); PD-1 
(EH12.2H7) (Biolegend San Diego, CA); MCSP (EP-1) (Miltenyi Biotec,Bergisch 
Gladbach, Germany) and BRAF (EP152Y) (Epitomics Burlingame, CA). Intracellular 
antigens were stained after fixation and permeabilization using Foxp3 intracellular 
staining Kit (ebiosciences). Stained cells were analyzed using a FACScanto II flow 
cytometer, or a FacsCaliber flow cytometer (BD Biosciences San Jose CA). Data 
was analyzed using Flowjo analysis software (Treestar Ashland OR). 
 
Cytokine detection  
 
Supernatants from cell lines or co-cultures were collected and aliquots stored at -
20°C prior to detection of IFN-γ, IL-1α, IL-1β, by standard ELISA methods according 
to manufacturer’s instructions (R&D Systems Minneapolis, MN). For some 
experiments supernatants were analyzed for multiple cytokines (IL-1α, IL-1β, IL-8, 
IL-6, MCP-1, CXCL-1, IFN-γ and TNF-α) by multiplex Luminex assays according to 
manufacturer’s instructions (Millipore Bedford, MA). 
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TIL suppression assay  
 
Foreskin-derived dermal cell preparations or melanoma TAFs were plated into 96-
well flat bottom plates and cultured until 80% confluent. Interleukin-1 α/β (1 ng/ml) 
or conditioned medium was added overnight. To test direct presentation, wells were 
washed prior to Mart-1 27L (AAGIGILTV) peptide pulsing (100 nM, 3hrs, 37°C, 
serum free medium). For third-party cell stimulation, T2 cells or irradiated CD40L-
activated B cells were pulsed with peptide and added with 1E5 Til at a 1:1 ratio to 
cultures. Proliferation was inferred by expression of cell cycle protein Ki-67 in the 
Mart-1 tetramer binding CD8 T cells. Supernatants were collected at the indicated 
times during the coculture for IFN-γ analysis as described above. Melanoma cell 
line conditioned medium was obtained from confluent cell cultures in T150 flasks 
containing 13 mL of medium after 24 hours with and without treatment with 1 mM 
Vemurafenib (Plexxikon Berkeley, CA). This treatment condition did not significantly 
alter the cell number/ flask. Medium was centrifuged and 0.22 mM filtered prior to 
use in assays. Blockade of PD-L1 and PD-L2 was achieved with the use of purified 
Azide free PD-L1 (M1H1), PD-L2 (MIH18) antibodies (BD Biosciences) at 1.5 
mg/mL doses. The COX-2 inhibitor NS398 (Cayman Chemicals Ann Arbor, 
Michigan) and DMSO vehicle controls were used at the time of IL-1 treatment at 50 
mM. IL-1α and IL-1β neutralizing antibodies (R&D Systems) were used at 20ug/mL 
each; isotype antibody (R&D Systems) controls were included where indicated. 
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Tissue Collection and Mutational Analysis  
 
Additional tissue was available for analysis on a subset of patients in the IHC 
analysis of IL-1α/β expression. From tissue at MDACC, patients either had results 
of Clinical Laboratory Improvement Amendment (CLIA) certified pyrosequencing of 
BRAF (exon 15) and NRAS (codons 12, 13, 61). For the remaining patients at 
MDACC who did not have CLIA mutational analysis done formalin-fixed paraffin 
embedded (FFPE) tissues were analyzed. The MDACC Biospecimen Core Facility 
extracted DNA from samples with at least 50% tumor content. Mass-spectroscopy 
genotyping for BRAF (exon 15) and NRAS (codons 12, 13, 61) mutations was 
performed as previously described. Patients without a BRAF or NRAS mutation 
were classified as wild-type (wt/wt). 
 
Immunohistochemistry and Scoring method  
 
IHC staining was conducted as previously described using primary IL-1α (LS-
B1581, 1:100) (LifeSpan Biosciences Seattle, WA) and IL-1β (sc-7884, 1:50) (Santa 
Cruz Biotechnology Santa Cruz, CA). Cores were scored as positive or negative for 
IL-1α or IL-1β immunoreactivity by three individuals. The percentage of staining 
cells in each core and the intensity of staining was scored from 1-3. The product of 
both values was used to determine a summary staining score. Scores were 
compiled and then reported 
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BRAF Knock Down Cell lines  
 
WM793p2 cells lines were transduced with lentiviral particles to introduce the 
pTRIPz construct from Open Bio Systems containing either a nonsilencing 
shRNAmir sequence (RHS4743), or a BRAF targeting shRNAmir with the BRAF 
antisense sequence, (V2THS_262034) CAGATGAAGATCATCGAAA. Cells were 
cultured in 2 ug/mL Doxycycline for 11 or 14 days and IL-1a measured by 
intracellular staining and FACs analysis, as described in main text. 
 
  
	  146	  	  
References 
[1] C.M. Balch, J.E. Gershenwald, S.J. Soong, J.F. Thompson, M.B. Atkins, D.R. 
Byrd, A.C. Buzaid, A.J. Cochran, D.G. Coit, S. Ding, A.M. Eggermont, K.T. 
Flaherty, P.A. Gimotty, J.M. Kirkwood, K.M. McMasters, M.C. Mihm, Jr., D.L. 
Morton, M.I. Ross, A.J. Sober, V.K. Sondak, Final version of 2009 AJCC 
melanoma staging and classification, J Clin Oncol 27 (2009) 6199-6206. 
[2] M.R. Middleton, J.J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen, S. Seiter, M. 
Gore, S. Aamdal, J. Cebon, A. Coates, B. Dreno, M. Henz, D. Schadendorf, 
A. Kapp, J. Weiss, U. Fraass, P. Statkevich, M. Muller, N. Thatcher, 
Randomized phase III study of temozolomide versus dacarbazine in the 
treatment of patients with advanced metastatic malignant melanoma, J Clin 
Oncol 18 (2000) 158-166. 
[3] S.S. Agarwala, Current systemic therapy for metastatic melanoma, Expert Rev 
Anticancer Ther 9 (2009) 587-595. 
[4] A.M. Eggermont, J.M. Kirkwood, Re-evaluating the role of dacarbazine in 
metastatic melanoma: what have we learned in 30 years?, Eur J Cancer 40 
(2004) 1825-1836. 
[5] T. Petrella, I. Quirt, S. Verma, A.E. Haynes, M. Charette, K. Bak, C. Melanoma 
Disease Site Group of Cancer Care Ontario's Program in Evidence-based, 
Single-agent interleukin-2 in the treatment of metastatic melanoma: a 
systematic review, Cancer Treat Rev 33 (2007) 484-496. 
[6] D.L. Brassard, M.J. Grace, R.W. Bordens, Interferon-alpha as an 
immunotherapeutic protein, J Leukoc Biol 71 (2002) 565-581. 
	  147	  	  
[7] A.J. Miller, M.C. Mihm, Jr., Melanoma, The New England journal of medicine 355 
(2006) 51-65. 
[8] R.D. Schreiber, L.J. Old, M.J. Smyth, Cancer immunoediting: integrating 
immunity's roles in cancer suppression and promotion, Science 331 (2011) 
1565-1570. 
[9] E.D. Reynoso, S.J. Turley, Unconventional antigen-presenting cells in the 
induction of peripheral CD8(+) T cell tolerance, J Leukoc Biol 86 (2009) 795-
801. 
[10] C. Barrow, J. Browning, D. MacGregor, I.D. Davis, S. Sturrock, A.A. Jungbluth, 
J. Cebon, Tumor antigen expression in melanoma varies according to 
antigen and stage, Clin Cancer Res 12 (2006) 764-771. 
[11] O.R. LA, L. Tai, L. Lee, E.A. Kruse, S. Grabow, W.D. Fairlie, N.M. Haynes, 
D.M. Tarlinton, J.G. Zhang, G.T. Belz, M.J. Smyth, P. Bouillet, L. Robb, A. 
Strasser, Membrane-bound Fas ligand only is essential for Fas-induced 
apoptosis, Nature 461 (2009) 659-663. 
[12] J.A. Trapani, M.J. Smyth, Functional significance of the perforin/granzyme cell 
death pathway, Nat Rev Immunol 2 (2002) 735-747. 
[13] A. Zippelius, P. Batard, V. Rubio-Godoy, G. Bioley, D. Lienard, F. Lejeune, D. 
Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, N. Rufer, N. 
Lubenow, D. Speiser, J.C. Cerottini, P. Romero, M.J. Pittet, Effector function 
of human tumor-specific CD8 T cells in melanoma lesions: a state of local 
functional tolerance, Cancer Res 64 (2004) 2865-2873. 
	  148	  	  
[14] S. Radoja, M. Saio, D. Schaer, M. Koneru, S. Vukmanovic, A.B. Frey, CD8(+) 
tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity 
due to defective microtubule-organizing center mobilization and lytic granule 
exocytosis, J Immunol 167 (2001) 5042-5051. 
[15] S.E. Street, J.A. Trapani, D. MacGregor, M.J. Smyth, Suppression of 
lymphoma and epithelial malignancies effected by interferon gamma, J Exp 
Med 196 (2002) 129-134. 
[16] M.J. Smyth, K.Y. Thia, S.E. Street, D. MacGregor, D.I. Godfrey, J.A. Trapani, 
Perforin-mediated cytotoxicity is critical for surveillance of spontaneous 
lymphoma, J Exp Med 192 (2000) 755-760. 
[17] M.E. van den Broek, D. Kagi, F. Ossendorp, R. Toes, S. Vamvakas, W.K. Lutz, 
C.J. Melief, R.M. Zinkernagel, H. Hengartner, Decreased tumor surveillance 
in perforin-deficient mice, J Exp Med 184 (1996) 1781-1790. 
[18] R. Clementi, F. Locatelli, L. Dupre, A. Garaventa, L. Emmi, M. Bregni, G. 
Cefalo, A. Moretta, C. Danesino, M. Comis, A. Pession, U. Ramenghi, R. 
Maccario, M. Arico, M.G. Roncarolo, A proportion of patients with lymphoma 
may harbor mutations of the perforin gene, Blood 105 (2005) 4424-4428. 
[19] A.S. Dighe, E. Richards, L.J. Old, R.D. Schreiber, Enhanced in vivo growth and 
resistance to rejection of tumor cells expressing dominant negative IFN 
gamma receptors, Immunity 1 (1994) 447-456. 
[20] J.A. Gollob, C.J. Sciambi, Z. Huang, H.K. Dressman, Gene expression changes 
and signaling events associated with the direct antimelanoma effect of IFN-
gamma, Cancer Res 65 (2005) 8869-8877. 
	  149	  	  
[21] S.E. Street, E. Cretney, M.J. Smyth, Perforin and interferon-gamma activities 
independently control tumor initiation, growth, and metastasis, Blood 97 
(2001) 192-197. 
[22] V. Shankaran, H. Ikeda, A.T. Bruce, J.M. White, P.E. Swanson, L.J. Old, R.D. 
Schreiber, IFNgamma and lymphocytes prevent primary tumour development 
and shape tumour immunogenicity, Nature 410 (2001) 1107-1111. 
[23] D.H. Kaplan, V. Shankaran, A.S. Dighe, E. Stockert, M. Aguet, L.J. Old, R.D. 
Schreiber, Demonstration of an interferon gamma-dependent tumor 
surveillance system in immunocompetent mice, Proc Natl Acad Sci U S A 95 
(1998) 7556-7561. 
[24] E. Zorn, T. Hercend, A natural cytotoxic T cell response in a spontaneously 
regressing human melanoma targets a neoantigen resulting from a somatic 
point mutation, Eur J Immunol 29 (1999) 592-601. 
[25] C.J. Arum, E. Anderssen, T. Viset, Y. Kodama, S. Lundgren, D. Chen, C.M. 
Zhao, Cancer immunoediting from immunosurveillance to tumor escape in 
microvillus-formed niche: a study of syngeneic orthotopic rat bladder cancer 
model in comparison with human bladder cancer, Neoplasia 12 (2010) 434-
442. 
[26] G.P. Dunn, A.T. Bruce, H. Ikeda, L.J. Old, R.D. Schreiber, Cancer 
immunoediting: from immunosurveillance to tumor escape, Nat Immunol 3 
(2002) 991-998. 
[27] G.P. Dunn, L.J. Old, R.D. Schreiber, The three Es of cancer immunoediting, 
Annual review of immunology 22 (2004) 329-360. 
	  150	  	  
[28] P.F. Robbins, M. El-Gamil, Y.F. Li, Y. Kawakami, D. Loftus, E. Appella, S.A. 
Rosenberg, A mutated beta-catenin gene encodes a melanoma-specific 
antigen recognized by tumor infiltrating lymphocytes, J Exp Med 183 (1996) 
1185-1192. 
[29] B. Linard, S. Bezieau, H. Benlalam, N. Labarriere, Y. Guilloux, E. Diez, F. 
Jotereau, A ras-mutated peptide targeted by CTL infiltrating a human 
melanoma lesion, J Immunol 168 (2002) 4802-4808. 
[30] B. Gaugler, B. Van den Eynde, P. van der Bruggen, P. Romero, J.J. Gaforio, E. 
De Plaen, B. Lethe, F. Brasseur, T. Boon, Human gene MAGE-3 codes for 
an antigen recognized on a melanoma by autologous cytolytic T 
lymphocytes, J Exp Med 179 (1994) 921-930. 
[31] D. Rimoldi, V. Rubio-Godoy, V. Dutoit, D. Lienard, S. Salvi, P. Guillaume, D. 
Speiser, E. Stockert, G. Spagnoli, C. Servis, J.C. Cerottini, F. Lejeune, P. 
Romero, D. Valmori, Efficient simultaneous presentation of NY-ESO-
1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes 
in melanoma, J Immunol 165 (2000) 7253-7261. 
[32] Y. Kawakami, S. Eliyahu, K. Sakaguchi, P.F. Robbins, L. Rivoltini, J.R. 
Yannelli, E. Appella, S.A. Rosenberg, Identification of the immunodominant 
peptides of the MART-1 human melanoma antigen recognized by the 
majority of HLA-A2-restricted tumor infiltrating lymphocytes, J Exp Med 180 
(1994) 347-352. 
[33] R. Lupetti, P. Pisarra, A. Verrecchia, C. Farina, G. Nicolini, A. Anichini, C. 
Bordignon, M. Sensi, G. Parmiani, C. Traversari, Translation of a retained 
	  151	  	  
intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic 
T lymphocyte (CTL)-defined and shared human melanoma antigen not 
expressed in normal cells of the melanocytic lineage, J Exp Med 188 (1998) 
1005-1016. 
[34] M. Ayyoub, M. Migliaccio, P. Guillaume, D. Lienard, J.C. Cerottini, P. Romero, 
F. Levy, D.E. Speiser, D. Valmori, Lack of tumor recognition by hTERT 
peptide 540-548-specific CD8(+) T cells from melanoma patients reveals 
inefficient antigen processing, Eur J Immunol 31 (2001) 2642-2651. 
[35] Y. Godet, A. Moreau-Aubry, Y. Guilloux, V. Vignard, A. Khammari, B. Dreno, F. 
Jotereau, N. Labarriere, MELOE-1 is a new antigen overexpressed in 
melanomas and involved in adoptive T cell transfer efficiency, J Exp Med 205 
(2008) 2673-2682. 
[36] J.B. Haanen, A. Baars, R. Gomez, P. Weder, M. Smits, T.D. de Gruijl, B.M. von 
Blomberg, E. Bloemena, R.J. Scheper, S.M. van Ham, H.M. Pinedo, A.J. van 
den Eertwegh, Melanoma-specific tumor-infiltrating lymphocytes but not 
circulating melanoma-specific T cells may predict survival in resected 
advanced-stage melanoma patients, Cancer immunology, immunotherapy : 
CII 55 (2006) 451-458. 
[37] Y. Naito, K. Saito, K. Shiiba, A. Ohuchi, K. Saigenji, H. Nagura, H. Ohtani, 
CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in 
human colorectal cancer, Cancer Res 58 (1998) 3491-3494. 
	  152	  	  
[38] C.G. Clemente, M.C. Mihm, Jr., R. Bufalino, S. Zurrida, P. Collini, N. Cascinelli, 
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase 
of primary cutaneous melanoma, Cancer 77 (1996) 1303-1310. 
[39] A. Anichini, C. Vegetti, R. Mortarini, The paradox of T-cell-mediated antitumor 
immunity in spite of poor clinical outcome in human melanoma, Cancer 
immunology, immunotherapy : CII 53 (2004) 855-864. 
[40] S. Ostrand-Rosenberg, Myeloid-derived suppressor cells: more mechanisms 
for inhibiting antitumor immunity, Cancer immunology, immunotherapy : CII 
59 (2010) 1593-1600. 
[41] I. Poschke, D. Mougiakakos, R. Kiessling, Camouflage and sabotage: tumor 
escape from the immune system, Cancer immunology, immunotherapy : CII 
(2011). 
[42] G. Lizee, M.A. Cantu, P. Hwu, Less yin, more yang: confronting the barriers to 
cancer immunotherapy, Clinical cancer research 13 (2007) 5250-5255. 
[43] G. Lizee, L.G. Radvanyi, W.W. Overwijk, P. Hwu, Improving antitumor immune 
responses by circumventing immunoregulatory cells and mechanisms, Clin 
Cancer Res 12 (2006) 4794-4803. 
[44] G. Lizee, L.G. Radvanyi, W.W. Overwijk, P. Hwu, Immunosuppression in 
melanoma immunotherapy: potential opportunities for intervention, Clin 
Cancer Res 12 (2006) 2359s-2365s. 
[45] G.A. Rabinovich, D. Gabrilovich, E.M. Sotomayor, Immunosuppressive 
strategies that are mediated by tumor cells, Annual review of immunology 25 
(2007) 267-296. 
	  153	  	  
[46] M.M. Fernando, C.R. Stevens, E.C. Walsh, P.L. De Jager, P. Goyette, R.M. 
Plenge, T.J. Vyse, J.D. Rioux, Defining the role of the MHC in autoimmunity: 
a review and pooled analysis, PLoS Genet 4 (2008) e1000024. 
[47] C. Blank, I. Brown, A.C. Peterson, M. Spiotto, Y. Iwai, T. Honjo, T.F. Gajewski, 
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor 
(TCR) transgenic CD8+ T cells, Cancer Res 64 (2004) 1140-1145. 
[48] Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, N. Minato, Involvement of 
PD-L1 on tumor cells in the escape from host immune system and tumor 
immunotherapy by PD-L1 blockade, Proc Natl Acad Sci U S A 99 (2002) 
12293-12297. 
[49] S.E. Strome, H. Dong, H. Tamura, S.G. Voss, D.B. Flies, K. Tamada, D. 
Salomao, J. Cheville, F. Hirano, W. Lin, J.L. Kasperbauer, K.V. Ballman, L. 
Chen, B7-H1 blockade augments adoptive T-cell immunotherapy for 
squamous cell carcinoma, Cancer Res 63 (2003) 6501-6505. 
[50] M. Ahmadzadeh, L.A. Johnson, B. Heemskerk, J.R. Wunderlich, M.E. Dudley, 
D.E. White, S.A. Rosenberg, Tumor antigen-specific CD8 T cells infiltrating 
the tumor express high levels of PD-1 and are functionally impaired, Blood 
114 (2009) 1537-1544. 
[51] R. Berger, R. Rotem-Yehudar, G. Slama, S. Landes, A. Kneller, M. Leiba, M. 
Koren-Michowitz, A. Shimoni, A. Nagler, Phase I safety and pharmacokinetic 
study of CT-011, a humanized antibody interacting with PD-1, in patients with 
advanced hematologic malignancies, Clin Cancer Res 14 (2008) 3044-3051. 
	  154	  	  
[52] J.R. Brahmer, C.G. Drake, I. Wollner, J.D. Powderly, J. Picus, W.H. Sharfman, 
E. Stankevich, A. Pons, T.M. Salay, T.L. McMiller, M.M. Gilson, C. Wang, M. 
Selby, J.M. Taube, R. Anders, L. Chen, A.J. Korman, D.M. Pardoll, I. Lowy, 
S.L. Topalian, Phase I study of single-agent anti-programmed death-1 (MDX-
1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, 
and immunologic correlates, J Clin Oncol 28 (2010) 3167-3175. 
[53] P.S. Linsley, W. Brady, L. Grosmaire, A. Aruffo, N.K. Damle, J.A. Ledbetter, 
Binding of the B cell activation antigen B7 to CD28 costimulates T cell 
proliferation and interleukin 2 mRNA accumulation, J Exp Med 173 (1991) 
721-730. 
[54] C.C. Stamper, Y. Zhang, J.F. Tobin, D.V. Erbe, S. Ikemizu, S.J. Davis, M.L. 
Stahl, J. Seehra, W.S. Somers, L. Mosyak, Crystal structure of the B7-
1/CTLA-4 complex that inhibits human immune responses, Nature 410 
(2001) 608-611. 
[55] J.C. Schwartz, X. Zhang, A.A. Fedorov, S.G. Nathenson, S.C. Almo, Structural 
basis for co-stimulation by the human CTLA-4/B7-2 complex, Nature 410 
(2001) 604-608. 
[56] R.V. Parry, J.M. Chemnitz, K.A. Frauwirth, A.R. Lanfranco, I. Braunstein, S.V. 
Kobayashi, P.S. Linsley, C.B. Thompson, J.L. Riley, CTLA-4 and PD-1 
receptors inhibit T-cell activation by distinct mechanisms, Mol Cell Biol 25 
(2005) 9543-9553. 
[57] M.A. Curran, W. Montalvo, H. Yagita, J.P. Allison, PD-1 and CTLA-4 
combination blockade expands infiltrating T cells and reduces regulatory T 
	  155	  	  
and myeloid cells within B16 melanoma tumors, Proc Natl Acad Sci U S A 
107 (2010) 4275-4280. 
[58] F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. 
Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J.C. Hassel, W. Akerley, 
A.J. van den Eertwegh, J. Lutzky, P. Lorigan, J.M. Vaubel, G.P. Linette, D. 
Hogg, C.H. Ottensmeier, C. Lebbe, C. Peschel, I. Quirt, J.I. Clark, J.D. 
Wolchok, J.S. Weber, J. Tian, M.J. Yellin, G.M. Nichol, A. Hoos, W.J. Urba, 
Improved survival with ipilimumab in patients with metastatic melanoma, The 
New England journal of medicine 363 (2010) 711-723. 
[59] S.J. O'Day, M. Maio, V. Chiarion-Sileni, T.F. Gajewski, H. Pehamberger, I.N. 
Bondarenko, P. Queirolo, L. Lundgren, S. Mikhailov, L. Roman, C. 
Verschraegen, R. Humphrey, R. Ibrahim, V. de Pril, A. Hoos, J.D. Wolchok, 
Efficacy and safety of ipilimumab monotherapy in patients with pretreated 
advanced melanoma: a multicenter single-arm phase II study, Ann Oncol 21 
(2010) 1712-1717. 
[60] J.D. Wolchok, B. Neyns, G. Linette, S. Negrier, J. Lutzky, L. Thomas, W. 
Waterfield, D. Schadendorf, M. Smylie, T. Guthrie, Jr., J.J. Grob, J. Chesney, 
K. Chin, K. Chen, A. Hoos, S.J. O'Day, C. Lebbe, Ipilimumab monotherapy in 
patients with pretreated advanced melanoma: a randomised, double-blind, 
multicentre, phase 2, dose-ranging study, Lancet Oncol 11 (2010) 155-164. 
[61] J. Weber, Ipilimumab: controversies in its development, utility and autoimmune 
adverse events, Cancer immunology, immunotherapy : CII 58 (2009) 823-
830. 
	  156	  	  
[62] L. Chin, The genetics of malignant melanoma: lessons from mouse and man, 
Nat Rev Cancer 3 (2003) 559-570. 
[63] H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, 
H. Woffendin, M.J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. 
Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. 
Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, 
B.A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. 
Maitland, G. Chenevix-Trench, G.J. Riggins, D.D. Bigner, G. Palmieri, A. 
Cossu, A. Flanagan, A. Nicholson, J.W. Ho, S.Y. Leung, S.T. Yuen, B.L. 
Weber, H.F. Seigler, T.L. Darrow, H. Paterson, R. Marais, C.J. Marshall, R. 
Wooster, M.R. Stratton, P.A. Futreal, Mutations of the BRAF gene in human 
cancer, Nature 417 (2002) 949-954. 
[64] J.H. Lee, J.W. Choi, Y.S. Kim, Frequencies of BRAF and NRAS mutations are 
different in histological types and sites of origin of cutaneous melanoma: a 
meta-analysis, The British journal of dermatology 164 (2011) 776-784. 
[65] P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, V.M. Good, 
C.M. Jones, C.J. Marshall, C.J. Springer, D. Barford, R. Marais, Mechanism 
of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-
RAF, Cell 116 (2004) 855-867. 
[66] COSMIC. 
[67] R. Houben, C.S. Vetter-Kauczok, S. Ortmann, U.R. Rapp, E.B. Broecker, J.C. 
Becker, Phospho-ERK staining is a poor indicator of the mutational status of 
	  157	  	  
BRAF and NRAS in human melanoma, J Invest Dermatol 128 (2008) 2003-
2012. 
[68] B. Jovanovic, D. Krockel, D. Linden, B. Nilsson, S. Egyhazi, J. Hansson, Lack 
of cytoplasmic ERK activation is an independent adverse prognostic factor in 
primary cutaneous melanoma, J Invest Dermatol 128 (2008) 2696-2704. 
[69] P. Uribe, L. Andrade, S. Gonzalez, Lack of association between BRAF mutation 
and MAPK ERK activation in melanocytic nevi, J Invest Dermatol 126 (2006) 
161-166. 
[70] J. Liu, K.G. Suresh Kumar, D. Yu, S.A. Molton, M. McMahon, M. Herlyn, A. 
Thomas-Tikhonenko, S.Y. Fuchs, Oncogenic BRAF regulates beta-Trcp 
expression and NF-kappaB activity in human melanoma cells, Oncogene 26 
(2007) 1954-1958. 
[71] Y. Estrada, J. Dong, L. Ossowski, Positive crosstalk between ERK and p38 in 
melanoma stimulates migration and in vivo proliferation, Pigment Cell 
Melanoma Res 22 (2009) 66-76. 
[72] K.P. Hoeflich, M.T. Eby, W.F. Forrest, D.C. Gray, J.Y. Tien, H.M. Stern, L.J. 
Murray, D.P. Davis, Z. Modrusan, S. Seshagiri, Regulation of ERK3/MAPK6 
expression by BRAF, Int J Oncol 29 (2006) 839-849. 
[73] Y. Aoyama, J. Avruch, X.F. Zhang, Nore1 inhibits tumor cell growth 
independent of Ras or the MST1/2 kinases, Oncogene 23 (2004) 3426-3433. 
[74] R. Houben, J.C. Becker, U.R. Rapp, Absence of mutations in the coding 
sequence of the potential tumor suppressor 3pK in metastatic melanoma, J 
Carcinog 4 (2005) 23. 
	  158	  	  
[75] O. Straume, L.A. Akslen, Strong expression of ID1 protein is associated with 
decreased survival, increased expression of ephrin-A1/EPHA2, and reduced 
thrombospondin-1 in malignant melanoma, Br J Cancer 93 (2005) 933-938. 
[76] A.H. Yeh, E.A. Bohula, V.M. Macaulay, Human melanoma cells expressing 
V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs, 
Oncogene 25 (2006) 6574-6581. 
[77] C. Hilmi, L. Larribere, S. Giuliano, K. Bille, J.P. Ortonne, R. Ballotti, C. 
Bertolotto, IGF1 promotes resistance to apoptosis in melanoma cells through 
an increased expression of BCL2, BCL-X(L), and survivin, J Invest Dermatol 
128 (2008) 1499-1505. 
[78] R.D. Kim, J.A. Curtin, B.C. Bastian, Lack of somatic alterations of MC1R in 
primary melanoma, Pigment Cell Melanoma Res 21 (2008) 579-582. 
[79] C.C. Pinnix, J.T. Lee, Z.J. Liu, R. McDaid, K. Balint, L.J. Beverly, P.A. Brafford, 
M. Xiao, B. Himes, S.E. Zabierowski, Y. Yashiro-Ohtani, K.L. Nathanson, A. 
Bengston, P.M. Pollock, A.T. Weeraratna, B.J. Nickoloff, W.S. Pear, A.J. 
Capobianco, M. Herlyn, Active Notch1 Confers a Transformed Phenotype to 
Primary Human Melanocytes, Cancer Res (2009). 
[80] C.S. Tellez, L. Shen, M.R. Estecio, J. Jelinek, J.E. Gershenwald, J.P. Issa, 
CpG island methylation profiling in human melanoma cell lines, Melanoma 
Res 19 (2009) 146-155. 
[81] D. Hanahan, R.A. Weinberg, The hallmarks of cancer, Cell 100 (2000) 57-70. 
	  159	  	  
[82] B. Zheng, J.H. Jeong, J.M. Asara, Y.Y. Yuan, S.R. Granter, L. Chin, L.C. 
Cantley, Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 
to promote melanoma cell proliferation, Mol Cell 33 (2009) 237-247. 
[83] H. Sumimoto, M. Miyagishi, H. Miyoshi, S. Yamagata, A. Shimizu, K. Taira, Y. 
Kawakami, Inhibition of growth and invasive ability of melanoma by 
inactivation of mutated BRAF with lentivirus-mediated RNA interference, 
Oncogene 23 (2004) 6031-6039. 
[84] H. Sumimoto, K. Hirata, S. Yamagata, H. Miyoshi, M. Miyagishi, K. Taira, Y. 
Kawakami, Effective inhibition of cell growth and invasion of melanoma by 
combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi, 
International journal of cancer. Journal international du cancer 118 (2006) 
472-476. 
[85] R. Esteve-Puig, F. Canals, N. Colome, G. Merlino, J.A. Recio, Uncoupling of 
the LKB1-AMPKalpha energy sensor pathway by growth factors and 
oncogenic BRAF, PLoS One 4 (2009) e4771. 
[86] A. Sharma, N.R. Trivedi, M.A. Zimmerman, D.A. Tuveson, C.D. Smith, G.P. 
Robertson, Mutant V599EB-Raf regulates growth and vascular development 
of malignant melanoma tumors, Cancer Res 65 (2005) 2412-2421. 
[87] M. Fisher, M. Abramov, A. Van Aerschot, J. Rozenski, V. Dixit, R.L. Juliano, P. 
Herdewijn, Biological effects of hexitol and altritol-modified siRNAs targeting 
B-Raf, Eur J Pharmacol 606 (2009) 38-44. 
	  160	  	  
[88] J. Goodall, S. Martinozzi, T.J. Dexter, D. Champeval, S. Carreira, L. Larue, 
C.R. Goding, Brn-2 expression controls melanoma proliferation and is 
directly regulated by beta-catenin, Mol Cell Biol 24 (2004) 2915-2922. 
[89] J. Goodall, C. Wellbrock, T.J. Dexter, K. Roberts, R. Marais, C.R. Goding, The 
Brn-2 transcription factor links activated BRAF to melanoma proliferation, Mol 
Cell Biol 24 (2004) 2923-2931. 
[90] Y. Zhao, Y. Zhang, Z. Yang, A. Li, J. Dong, Simultaneous knockdown of BRAF 
and expression of INK4A in melanoma cells leads to potent growth inhibition 
and apoptosis, Biochem Biophys Res Commun 370 (2008) 509-513. 
[91] Y. Cui, T.M. Guadagno, B-Raf(V600E) signaling deregulates the mitotic spindle 
checkpoint through stabilizing Mps1 levels in melanoma cells, Oncogene 27 
(2008) 3122-3133. 
[92] W. Liu, J.W. Kelly, M. Trivett, W.K. Murray, J.P. Dowling, R. Wolfe, G. Mason, 
J. Magee, C. Angel, A. Dobrovic, G.A. McArthur, Distinct clinical and 
pathological features are associated with the BRAF(T1799A(V600E)) 
mutation in primary melanoma, J Invest Dermatol 127 (2007) 900-905. 
[93] R. Hu, A.E. Aplin, Skp2 regulates G2/M progression in a p53-dependent 
manner, Mol Biol Cell 19 (2008) 4602-4610. 
[94] W.K. Kaufmann, K.R. Nevis, P. Qu, J.G. Ibrahim, T. Zhou, Y. Zhou, D.A. 
Simpson, J. Helms-Deaton, M. Cordeiro-Stone, D.T. Moore, N.E. Thomas, H. 
Hao, Z. Liu, J.M. Shields, G.A. Scott, N.E. Sharpless, Defective cell cycle 
checkpoint functions in melanoma are associated with altered patterns of 
gene expression, J Invest Dermatol 128 (2008) 175-187. 
	  161	  	  
[95] C. Wellbrock, S. Rana, H. Paterson, H. Pickersgill, T. Brummelkamp, R. 
Marais, Oncogenic BRAF regulates melanoma proliferation through the 
lineage specific factor MITF, PLoS One 3 (2008) e2734. 
[96] K.V. Bhatt, R. Hu, L.S. Spofford, A.E. Aplin, Mutant B-RAF signaling and cyclin 
D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation 
of p27Kip1 in human melanoma cells, Oncogene 26 (2007) 1056-1066. 
[97] K.V. Bhatt, L.S. Spofford, G. Aram, M. McMullen, K. Pumiglia, A.E. Aplin, 
Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma 
cells through BRAF-MEK-ERK signaling, Oncogene 24 (2005) 3459-3471. 
[98] S. Carreira, J. Goodall, I. Aksan, S.A. La Rocca, M.D. Galibert, L. Denat, L. 
Larue, C.R. Goding, Mitf cooperates with Rb1 and activates p21Cip1 
expression to regulate cell cycle progression, Nature 433 (2005) 764-769. 
[99] K.S. Smalley, M. Lioni, M. Dalla Palma, M. Xiao, B. Desai, S. Egyhazi, J. 
Hansson, H. Wu, A.J. King, P. Van Belle, D.E. Elder, K.T. Flaherty, M. 
Herlyn, K.L. Nathanson, Increased cyclin D1 expression can mediate BRAF 
inhibitor resistance in BRAF V600E-mutated melanomas, Mol Cancer Ther 7 
(2008) 2876-2883. 
[100] L.S. Spofford, E.V. Abel, K. Boisvert-Adamo, A.E. Aplin, Cyclin D3 expression 
in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 
3-kinase signaling and contributes to G1-S progression, J Biol Chem 281 
(2006) 25644-25651. 
	  162	  	  
[101] C. Christensen, P. Guldberg, Growth factors rescue cutaneous melanoma 
cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF, 
Oncogene 24 (2005) 6292-6302. 
[102] H. Hao, V.M. Muniz-Medina, H. Mehta, N.E. Thomas, V. Khazak, C.J. Der, 
J.M. Shields, Context-dependent roles of mutant B-Raf signaling in 
melanoma and colorectal carcinoma cell growth, Mol Cancer Ther 6 (2007) 
2220-2229. 
[103] S.R. Conner, G. Scott, A.E. Aplin, Adhesion-dependent activation of the 
ERK1/2 cascade is by-passed in melanoma cells, J Biol Chem 278 (2003) 
34548-34554. 
[104] S.M. Kumar, H. Yu, R. Edwards, L. Chen, S. Kazianis, P. Brafford, G. Acs, M. 
Herlyn, X. Xu, Mutant V600E BRAF increases hypoxia inducible factor-
1alpha expression in melanoma, Cancer Res 67 (2007) 3177-3184. 
[105] H. Sumimoto, F. Imabayashi, T. Iwata, Y. Kawakami, The BRAF-MAPK 
signaling pathway is essential for cancer-immune evasion in human 
melanoma cells, J Exp Med 203 (2006) 1651-1656. 
[106] C. Gaggioli, G. Robert, C. Bertolotto, O. Bailet, P. Abbe, A. Spadafora, P. 
Bahadoran, J.P. Ortonne, V. Baron, R. Ballotti, S. Tartare-Deckert, Tumor-
derived fibronectin is involved in melanoma cell invasion and regulated by 
V600E B-Raf signaling pathway, J Invest Dermatol 127 (2007) 400-410. 
[107] R.M. Klein, L.S. Spofford, E.V. Abel, A. Ortiz, A.E. Aplin, B-RAF regulation of 
Rnd3 participates in actin cytoskeletal and focal adhesion organization, Mol 
Biol Cell 19 (2008) 498-508. 
	  163	  	  
[108] G.M. Argast, C.H. Croy, K.L. Couts, Z. Zhang, E. Litman, D.C. Chan, N.G. 
Ahn, Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a 
tumor suppressor in melanoma cells, Oncogene (2009). 
[109] J.T. Huntington, J.M. Shields, C.J. Der, C.A. Wyatt, U. Benbow, C.L. Slingluff, 
Jr., C.E. Brinckerhoff, Overexpression of collagenase 1 (MMP-1) is mediated 
by the ERK pathway in invasive melanoma cells: role of BRAF mutation and 
fibroblast growth factor signaling, J Biol Chem 279 (2004) 33168-33176. 
[110] S. Liang, A. Sharma, H.H. Peng, G. Robertson, C. Dong, Targeting mutant 
(V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions 
and melanoma extravasation, Cancer Res 67 (2007) 5814-5820. 
[111] A. Sharma, M.A. Tran, S. Liang, A.K. Sharma, S. Amin, C.D. Smith, C. Dong, 
G.P. Robertson, Targeting mitogen-activated protein kinase/extracellular 
signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling 
cascade effectively inhibits melanoma lung metastases, Cancer Res 66 
(2006) 8200-8209. 
[112] S.R. Hingorani, M.A. Jacobetz, G.P. Robertson, M. Herlyn, D.A. Tuveson, 
Suppression of BRAF(V599E) in human melanoma abrogates 
transformation, Cancer Res 63 (2003) 5198-5202. 
[113] R.M. Klein, A.E. Aplin, Rnd3 regulation of the actin cytoskeleton promotes 
melanoma migration and invasive outgrowth in three dimensions, Cancer 
Res 69 (2009) 2224-2233. 
[114] W.M. Old, J.B. Shabb, S. Houel, H. Wang, K.L. Couts, C.Y. Yen, E.S. Litman, 
C.H. Croy, K. Meyer-Arendt, J.G. Miranda, R.A. Brown, E.S. Witze, R.E. 
	  164	  	  
Schweppe, K.A. Resing, N.G. Ahn, Functional proteomics identifies targets of 
phosphorylation by B-Raf signaling in melanoma, Mol Cell 34 (2009) 115-
131. 
[115] Y.F. Wang, C.C. Jiang, K.A. Kiejda, S. Gillespie, X.D. Zhang, P. Hersey, 
Apoptosis induction in human melanoma cells by inhibition of MEK is 
caspase-independent and mediated by the Bcl-2 family members PUMA, 
Bim, and Mcl-1, Clin Cancer Res 13 (2007) 4934-4942. 
[116] K. Boisvert-Adamo, W. Longmate, E.V. Abel, A.E. Aplin, Mcl-1 is required for 
melanoma cell resistance to anoikis, Mol Cancer Res 7 (2009) 549-556. 
[117] C. Sheridan, G. Brumatti, S.J. Martin, Oncogenic B-RafV600E inhibits 
apoptosis and promotes ERK-dependent inactivation of Bad and Bim, J Biol 
Chem 283 (2008) 22128-22135. 
[118] M.W. VanBrocklin, M. Verhaegen, M.S. Soengas, S.L. Holmen, Mitogen-
activated protein kinase inhibition induces translocation of Bmf to promote 
apoptosis in melanoma, Cancer Res 69 (2009) 1985-1994. 
[119] M. Verhaegen, J.A. Bauer, C. Martin de la Vega, G. Wang, K.G. Wolter, J.C. 
Brenner, Z. Nikolovska-Coleska, A. Bengtson, R. Nair, J.T. Elder, M. Van 
Brocklin, T.E. Carey, C.R. Bradford, S. Wang, M.S. Soengas, A novel BH3 
mimetic reveals a mitogen-activated protein kinase-dependent mechanism of 
melanoma cell death controlled by p53 and reactive oxygen species, Cancer 
Res 66 (2006) 11348-11359. 
[120] K. Boisvert-Adamo, A.E. Aplin, B-RAF and PI-3 kinase signaling protect 
melanoma cells from anoikis, Oncogene 25 (2006) 4848-4856. 
	  165	  	  
[121] N.B. Goldstein, W.U. Johannes, A.V. Gadeliya, M.R. Green, M. Fujita, D.A. 
Norris, Y.G. Shellman, Active N-Ras and B-Raf inhibit anoikis by 
downregulating Bim expression in melanocytic cells, J Invest Dermatol 129 
(2009) 432-437. 
[122] K. Boisvert-Adamo, A.E. Aplin, Mutant B-RAF mediates resistance to anoikis 
via Bad and Bim, Oncogene 27 (2008) 3301-3312. 
[123] M.M. McCarthy, E. Pick, Y. Kluger, B. Gould-Rothberg, R. Lazova, R.L. Camp, 
D.L. Rimm, H.M. Kluger, HSP90 as a marker of progression in melanoma, 
Ann Oncol 19 (2008) 590-594. 
[124] R.A. Cartlidge, G.R. Thomas, S. Cagnol, K.A. Jong, S.A. Molton, A.J. Finch, 
M. McMahon, Oncogenic BRAF(V600E) inhibits BIM expression to promote 
melanoma cell survival, Pigment Cell Melanoma Res 21 (2008) 534-544. 
[125] D. Dankort, D.P. Curley, R.A. Cartlidge, B. Nelson, A.N. Karnezis, W.E. 
Damsky, Jr., M.J. You, R.A. DePinho, M. McMahon, M. Bosenberg, 
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma, Nat 
Genet 41 (2009) 544-552. 
[126] V.K. Goel, N. Ibrahim, G. Jiang, M. Singhal, S. Fee, T. Flotte, S. 
Westmoreland, F.S. Haluska, P.W. Hinds, F.G. Haluska, Melanocytic nevus-
like hyperplasia and melanoma in transgenic BRAFV600E mice, Oncogene 
28 (2009) 2289-2298. 
[127] N. Dhomen, J.S. Reis-Filho, S. da Rocha Dias, R. Hayward, K. Savage, V. 
Delmas, L. Larue, C. Pritchard, R. Marais, Oncogenic Braf induces 
	  166	  	  
melanocyte senescence and melanoma in mice, Cancer Cell 15 (2009) 294-
303. 
[128] G. Bollag, P. Hirth, J. Tsai, J. Zhang, P.N. Ibrahim, H. Cho, W. Spevak, C. 
Zhang, Y. Zhang, G. Habets, E.A. Burton, B. Wong, G. Tsang, B.L. West, B. 
Powell, R. Shellooe, A. Marimuthu, H. Nguyen, K.Y. Zhang, D.R. Artis, J. 
Schlessinger, F. Su, B. Higgins, R. Iyer, K. D'Andrea, A. Koehler, M. Stumm, 
P.S. Lin, R.J. Lee, J. Grippo, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, 
J.A. Sosman, P.B. Chapman, K.T. Flaherty, X. Xu, K.L. Nathanson, K. Nolop, 
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-
mutant melanoma, Nature 467 (2010) 596-599. 
[129] T. Eisen, T. Ahmad, K.T. Flaherty, M. Gore, S. Kaye, R. Marais, I. Gibbens, S. 
Hackett, M. James, L.M. Schuchter, K.L. Nathanson, C. Xia, R. Simantov, B. 
Schwartz, M. Poulin-Costello, P.J. O'Dwyer, M.J. Ratain, Sorafenib in 
advanced melanoma: a Phase II randomised discontinuation trial analysis, Br 
J Cancer 95 (2006) 581-586. 
[130] K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, J.A. Sosman, 
P.J. O'Dwyer, R.J. Lee, J.F. Grippo, K. Nolop, P.B. Chapman, Inhibition of 
mutated, activated BRAF in metastatic melanoma, The New England journal 
of medicine 363 (2010) 809-819. 
[131] S. Rotolo, R. Diotti, R.E. Gordon, R.F. Qiao, Z. Yao, R.G. Phelps, J. Dong, 
Effects on proliferation and melanogenesis by inhibition of mutant BRAF and 
expression of wild-type INK4A in melanoma cells, International journal of 
cancer. Journal international du cancer 115 (2005) 164-169. 
	  167	  	  
[132] M. Kono, I.S. Dunn, P.J. Durda, D. Butera, L.B. Rose, T.J. Haggerty, E.M. 
Benson, J.T. Kurnick, Role of the mitogen-activated protein kinase signaling 
pathway in the regulation of human melanocytic antigen expression, Mol 
Cancer Res 4 (2006) 779-792. 
[133] A. Boni, A.P. Cogdill, P. Dang, D. Udayakumar, C.N. Njauw, C.M. Sloss, C.R. 
Ferrone, K.T. Flaherty, D.P. Lawrence, D.E. Fisher, H. Tsao, J.A. Wargo, 
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma 
without affecting lymphocyte function, Cancer Res 70 (2010) 5213-5219. 
[134] C. Haqq, M. Nosrati, D. Sudilovsky, J. Crothers, D. Khodabakhsh, B.L. 
Pulliam, S. Federman, J.R. Miller, 3rd, R.E. Allen, M.I. Singer, S.P. Leong, 
B.M. Ljung, R.W. Sagebiel, M. Kashani-Sabet, The gene expression 
signatures of melanoma progression, Proc Natl Acad Sci U S A 102 (2005) 
6092-6097. 
[135] P. Johansson, S. Pavey, N. Hayward, Confirmation of a BRAF mutation-
associated gene expression signature in melanoma, Pigment Cell Res 20 
(2007) 216-221. 
[136] J.M. Shields, N.E. Thomas, M. Cregger, A.J. Berger, M. Leslie, C. Torrice, H. 
Hao, S. Penland, J. Arbiser, G. Scott, T. Zhou, M. Bar-Eli, J.E. Bear, C.J. 
Der, W.K. Kaufmann, D.L. Rimm, N.E. Sharpless, Lack of extracellular 
signal-regulated kinase mitogen-activated protein kinase signaling shows a 
new type of melanoma, Cancer Res 67 (2007) 1502-1512. 
	  168	  	  
[137] D. Schrama, G. Keller, R. Houben, C.G. Ziegler, C.S. Vetter-Kauczok, S. 
Ugurel, J.C. Becker, BRAFV600E mutations in malignant melanoma are 
associated with increased expressions of BAALC, J Carcinog 7 (2008) 1. 
[138] S. Pavey, P. Johansson, L. Packer, J. Taylor, M. Stark, P.M. Pollock, G.J. 
Walker, G.M. Boyle, U. Harper, S.J. Cozzi, K. Hansen, L. Yudt, C. Schmidt, 
P. Hersey, K.A. Ellem, M.G. O'Rourke, P.G. Parsons, P. Meltzer, M. Ringner, 
N.K. Hayward, Microarray expression profiling in melanoma reveals a BRAF 
mutation signature, Oncogene 23 (2004) 4060-4067. 
[139] D. Tsavachidou, M.L. Coleman, G. Athanasiadis, S. Li, J.D. Licht, M.F. Olson, 
B.L. Weber, SPRY2 is an inhibitor of the ras/extracellular signal-regulated 
kinase pathway in melanocytes and melanoma cells with wild-type BRAF but 
not with the V599E mutant, Cancer Res 64 (2004) 5556-5559. 
[140] S. Nambiar, A. Mirmohammadsadegh, R. Doroudi, A. Gustrau, A. Marini, G. 
Roeder, T. Ruzicka, U.R. Hengge, Signaling networks in cutaneous 
melanoma metastasis identified by complementary DNA microarrays, Arch 
Dermatol 141 (2005) 165-173. 
[141] S. Bloethner, K. Hemminki, R.K. Thirumaran, B. Chen, J. Mueller-Berghaus, 
S. Ugurel, D. Schadendorf, R. Kumar, Differences in global gene expression 
in melanoma cell lines with and without homozygous deletion of the CDKN2A 
locus genes, Melanoma Res 16 (2006) 297-307. 
[142] J.A. Curtin, K. Busam, D. Pinkel, B.C. Bastian, Somatic activation of KIT in 
distinct subtypes of melanoma, J Clin Oncol 24 (2006) 4340-4346. 
	  169	  	  
[143] K.S. Hoek, N.C. Schlegel, P. Brafford, A. Sucker, S. Ugurel, R. Kumar, B.L. 
Weber, K.L. Nathanson, D.J. Phillips, M. Herlyn, D. Schadendorf, R. 
Dummer, Metastatic potential of melanomas defined by specific gene 
expression profiles with no BRAF signature, Pigment Cell Res 19 (2006) 
290-302. 
[144] B.N. Perry, C. Cohen, B. Govindarajan, G. Cotsonis, J.L. Arbiser, Wilms tumor 
1 expression present in most melanomas but nearly absent in nevi, Arch 
Dermatol 142 (2006) 1031-1034. 
[145] K.S. Hoek, DNA microarray analyses of melanoma gene expression: a 
decade in the mines, Pigment Cell Res 20 (2007) 466-484. 
[146] K.B. Petermann, G.I. Rozenberg, D. Zedek, P. Groben, K. McKinnon, C. 
Buehler, W.Y. Kim, J.M. Shields, S. Penland, J.E. Bear, N.E. Thomas, J.S. 
Serody, N.E. Sharpless, CD200 is induced by ERK and is a potential 
therapeutic target in melanoma, J Clin Invest 117 (2007) 3922-3929. 
[147] B. Dessars, L.E. De Raeve, R. Morandini, A. Lefort, H. El Housni, G.E. 
Ghanem, B.J. Van den Eynde, W. Ma, D. Roseeuw, G. Vassart, F. Libert, P. 
Heimann, Genotypic and gene expression studies in congenital melanocytic 
nevi: insight into initial steps of melanotumorigenesis, J Invest Dermatol 129 
(2009) 139-147. 
[148] G. Jonsson, C. Dahl, J. Staaf, T. Sandberg, P.O. Bendahl, M. Ringner, P. 
Guldberg, A. Borg, Genomic profiling of malignant melanoma using tiling-
resolution arrayCGH, Oncogene 26 (2007) 4738-4748. 
	  170	  	  
[149] C. Kannengiesser, A. Spatz, S. Michiels, A. Eychene, P. Dessen, V. Lazar, V. 
Winnepenninckx, F. Lesueur, S. Druillennec, C. Robert, J.J. van den Oord, 
A. Sarasin, B. Bressac-de Paillerets, Gene expression signature associated 
with BRAF mutations in human primary cutaneous melanomas, Mol Oncol 1 
(2008) 425-430. 
[150] S. Bloethner, B. Chen, K. Hemminki, J. Muller-Berghaus, S. Ugurel, D. 
Schadendorf, R. Kumar, Effect of common B-RAF and N-RAS mutations on 
global gene expression in melanoma cell lines, Carcinogenesis 26 (2005) 
1224-1232. 
[151] E. Lazar-Molnar, H. Hegyesi, S. Toth, A. Falus, Autocrine and paracrine 
regulation by cytokines and growth factors in melanoma, Cytokine 12 (2000) 
547-554. 
[152] O. Kholmanskikh, N. van Baren, F. Brasseur, S. Ottaviani, J. Vanacker, N. 
Arts, P. van der Bruggen, P. Coulie, E. De Plaen, Interleukins 1alpha and 
1beta secreted by some melanoma cell lines strongly reduce expression of 
MITF-M and melanocyte differentiation antigens, International journal of 
cancer. Journal international du cancer 127 (2010) 1625-1636. 
[153] D.S. Tyler, G.M. Francis, M. Frederick, A.H. Tran, N.G. Ordonez, J.L. Smith, 
O. Eton, M. Ross, E.A. Grimm, Interleukin-1 production in tumor cells of 
human melanoma surgical specimens, Journal of interferon & cytokine 
research : the official journal of the International Society for Interferon and 
Cytokine Research 15 (1995) 331-340. 
	  171	  	  
[154] L.D. True, H. Zhang, M. Ye, C.Y. Huang, P.S. Nelson, P.D. von Haller, L.W. 
Tjoelker, J.S. Kim, W.J. Qian, R.D. Smith, W.J. Ellis, E.S. Liebeskind, A.Y. 
Liu, CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts 
and could serve as a cancer biomarker, Mod Pathol 23 (2010) 1346-1356. 
[155] V. Paunescu, F.M. Bojin, C.A. Tatu, O.I. Gavriliuc, A. Rosca, A.T. Gruia, G. 
Tanasie, C. Bunu, D. Crisnic, M. Gherghiceanu, F.R. Tatu, C.S. Tatu, S. 
Vermesan, Tumour-associated fibroblasts and mesenchymal stem cells: 
more similarities than differences, J Cell Mol Med 15 (2011) 635-646. 
[156] L. Kisselbach, M. Merges, A. Bossie, A. Boyd, CD90 Expression on human 
primary cells and elimination of contaminating fibroblasts from cell cultures, 
Cytotechnology 59 (2009) 31-44. 
[157] J.R. Lukens, M.W. Cruise, M.G. Lassen, Y.S. Hahn, Blockade of PD-1/B7-H1 
interaction restores effector CD8+ T cell responses in a hepatitis C virus core 
murine model, J Immunol 180 (2008) 4875-4884. 
[158] M. Okano, Y. Sugata, T. Fujiwara, R. Matsumoto, M. Nishibori, K. Shimizu, M. 
Maeda, Y. Kimura, S. Kariya, H. Hattori, M. Yokoyama, K. Kino, K. Nishizaki, 
E prostanoid 2 (EP2)/EP4-mediated suppression of antigen-specific human 
T-cell responses by prostaglandin E2, Immunology 118 (2006) 343-352. 
[159] R. Beppu, K. Nakamura, H. Miyajima-Uchida, M. Kuroki, P.D. Khare, Y. 
Yamauchi, Y. Yamashita, T. Shirakusa, Soluble thrombospondin-1 
suppresses T cell proliferation and enhances IL-10 secretion by antigen 
presenting cells stimulated with phytohemagglutinin, Immunol Invest 30 
(2001) 143-156. 
	  172	  	  
[160] Y. Shav-Tal, D. Zipori, The role of activin a in regulation of hemopoiesis, Stem 
Cells 20 (2002) 493-500. 
[161] A. Chakraborty, H. Brooks, P. Zhang, W. Smith, M.R. McReynolds, J.B. 
Hoying, R. Bick, L. Truong, B. Poindexter, H. Lan, W. Elbjeirami, D. Sheikh-
Hamad, Stanniocalcin-1 regulates endothelial gene expression and 
modulates transendothelial migration of leukocytes, Am J Physiol Renal 
Physiol 292 (2007) F895-904. 
[162] N. Rouas-Freiss, P. Moreau, C. Menier, J. LeMaoult, E.D. Carosella, 
Expression of tolerogenic HLA-G molecules in cancer prevents antitumor 
responses, Semin Cancer Biol 17 (2007) 413-421. 
[163] A. Siva, H. Xin, F. Qin, D. Oltean, K.S. Bowdish, A. Kretz-Rommel, Immune 
modulation by melanoma and ovarian tumor cells through expression of the 
immunosuppressive molecule CD200, Cancer immunology, immunotherapy : 
CII 57 (2008) 987-996. 
[164] S. Huber, R. Hoffmann, F. Muskens, D. Voehringer, Alternatively activated 
macrophages inhibit T-cell proliferation by Stat6-dependent expression of 
PD-L2, Blood 116 (2010) 3311-3320. 
[165] M. Najar, G. Raicevic, H.I. Boufker, H. Fayyad-Kazan, C. De Bruyn, N. 
Meuleman, D. Bron, M. Toungouz, L. Lagneaux, Adipose-tissue-derived and 
Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte 
responses by secreting leukemia inhibitory factor, Tissue Eng Part A 16 
(2010) 3537-3546. 
	  173	  	  
[166] B. Zhang, CD73: a novel target for cancer immunotherapy, Cancer Res 70 
(2010) 6407-6411. 
[167] S.F. Ziegler, D. Artis, Sensing the outside world: TSLP regulates barrier 
immunity, Nat Immunol 11 (2010) 289-293. 
[168] M.E. Dudley, J.R. Wunderlich, J.C. Yang, R.M. Sherry, S.L. Topalian, N.P. 
Restifo, R.E. Royal, U. Kammula, D.E. White, S.A. Mavroukakis, L.J. Rogers, 
G.J. Gracia, S.A. Jones, D.P. Mangiameli, M.M. Pelletier, J. Gea-
Banacloche, M.R. Robinson, D.M. Berman, A.C. Filie, A. Abati, S.A. 
Rosenberg, Adoptive cell transfer therapy following non-myeloablative but 
lymphodepleting chemotherapy for the treatment of patients with refractory 
metastatic melanoma, Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 23 (2005) 2346-2357. 
[169] M.J. Besser, R. Shapira-Frommer, A.J. Treves, D. Zippel, O. Itzhaki, L. 
Hershkovitz, D. Levy, A. Kubi, E. Hovav, N. Chermoshniuk, B. Shalmon, I. 
Hardan, R. Catane, G. Markel, S. Apter, A. Ben-Nun, I. Kuchuk, A. Shimoni, 
A. Nagler, J. Schachter, Clinical responses in a phase II study using adoptive 
transfer of short-term cultured tumor infiltration lymphocytes in metastatic 
melanoma patients, Clinical cancer research 16 (2010) 2646-2655. 
[170] T. Scholzen, J. Gerdes, The Ki-67 protein: from the known and the unknown, 
J Cell Physiol 182 (2000) 311-322. 
[171] M.C. Heinrich, C.L. Corless, Cancer: Oncogenes in context, Nature 467 
(2010) 796-797. 
	  174	  	  
[172] K. Forrester, C. Almoguera, K. Han, W.E. Grizzle, M. Perucho, Detection of 
high incidence of K-ras oncogenes during human colon tumorigenesis, 
Nature 327 (1987) 298-303. 
[173] C. Almoguera, D. Shibata, K. Forrester, J. Martin, N. Arnheim, M. Perucho, 
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras 
genes, Cell 53 (1988) 549-554. 
[174] M.C. Heinrich, C.L. Corless, A. Duensing, L. McGreevey, C.J. Chen, N. 
Joseph, S. Singer, D.J. Griffith, A. Haley, A. Town, G.D. Demetri, C.D. 
Fletcher, J.A. Fletcher, PDGFRA activating mutations in gastrointestinal 
stromal tumors, Science 299 (2003) 708-710. 
[175] S. Hirota, K. Isozaki, Y. Moriyama, K. Hashimoto, T. Nishida, S. Ishiguro, K. 
Kawano, M. Hanada, A. Kurata, M. Takeda, G. Muhammad Tunio, Y. 
Matsuzawa, Y. Kanakura, Y. Shinomura, Y. Kitamura, Gain-of-function 
mutations of c-kit in human gastrointestinal stromal tumors, Science 279 
(1998) 577-580. 
[176] R.A. Padua, N. Barrass, G.A. Currie, A novel transforming gene in a human 
malignant melanoma cell line, Nature 311 (1984) 671-673. 
[177] S.E. Woodman, M.A. Davies, Targeting KIT in melanoma: a paradigm of 
molecular medicine and targeted therapeutics, Biochemical pharmacology 80 
(2010) 568-574. 
[178] K.T. Flaherty, F.S. Hodi, B.C. Bastian, Mutation-driven drug development in 
melanoma, Current opinion in oncology 22 (2010) 178-183. 
	  175	  	  
[179] R. Dummer, C. Robert, P. Chapman, J. Sosman, M.R. Middleton, L. Bastholt, 
K. Kemsley, M.V. Cantarini, C. Morris, J.M. Kirkwood, AZD6244 (ARR-
142886) vs temozolomide (TMZ) in patients with advanced melanoma: an 
open-label, randomized, multicenter, phase II study, J Clin Oncol 26 (2008) 
9033. 
[180] A.A. Adjei, R.B. Cohen, W. Franklin, C. Morris, D. Wilson, J.R. Molina, L.J. 
Hanson, L. Gore, L. Chow, S. Leong, L. Maloney, G. Gordon, H. Simmons, 
A. Marlow, K. Litwiler, S. Brown, G. Poch, K. Kane, J. Haney, S.G. Eckhardt, 
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-
molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 
(ARRY-142886) in patients with advanced cancers, J Clin Oncol 26 (2008) 
2139-2146. 
[181] F.A. Schutz, Y. Je, T.K. Choueiri, Hematologic toxicities in cancer patients 
treated with the multi-tyrosine kinase sorafenib: A meta-analysis of clinical 
trials, Crit Rev Oncol Hematol. 
[182] R. Weichsel, C. Dix, L. Wooldridge, M. Clement, A. Fenton-May, A.K. Sewell, 
J. Zezula, E. Greiner, E. Gostick, D.A. Price, H. Einsele, R. Seggewiss, 
Profound inhibition of antigen-specific T-cell effector functions by dasatinib, 
Clin Cancer Res 14 (2008) 2484-2491. 
[183] P. Rohon, K. Porkka, S. Mustjoki, Immunoprofiling of patients with chronic 
myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy, 
Eur J Haematol 85 387-398. 
	  176	  	  
[184] C. Dong, R.J. Davis, R.A. Flavell, MAP kinases in the immune response, 
Annual review of immunology 20 (2002) 55-72. 
[185] S.C. Bendall, E.F. Simonds, P. Qiu, A.D. Amir el, P.O. Krutzik, R. Finck, R.V. 
Bruggner, R. Melamed, A. Trejo, O.I. Ornatsky, R.S. Balderas, S.K. Plevritis, 
K. Sachs, D. Pe'er, S.D. Tanner, G.P. Nolan, Single-cell mass cytometry of 
differential immune and drug responses across a human hematopoietic 
continuum, Science 332 (2011) 687-696. 
[186] I. Poschke, D. Mougiakakos, J. Hansson, G.V. Masucci, R. Kiessling, 
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma 
patients are Stat3hi and overexpress CD80, CD83, and DC-sign, Cancer Res 
70 4335-4345. 
[187] D.R. Green, T. Ferguson, L. Zitvogel, G. Kroemer, Immunogenic and 
tolerogenic cell death, Nat Rev Immunol 9 (2009) 353-363. 
[188] M.H. Kulke, E.A. Vance, Pneumocystis carinii pneumonia in patients receiving 
chemotherapy for breast cancer, Clin Infect Dis 25 (1997) 215-218. 
[189] O. Kepp, A. Tesniere, L. Zitvogel, G. Kroemer, The immunogenicity of tumor 
cell death, Current opinion in oncology 21 (2009) 71-76. 
[190] L. Zitvogel, L. Apetoh, F. Ghiringhelli, F. Andre, A. Tesniere, G. Kroemer, The 
anticancer immune response: indispensable for therapeutic success?, J Clin 
Invest 118 (2008) 1991-2001. 
[191] P.A. Ott, S. Adams, Small-molecule protein kinase inhibitors and their effects 
on the immune system: implications for cancer treatment, Immunotherapy 3 
(2011) 213-227. 
	  177	  	  
[192] D.B. Solit, N. Rosen, Resistance to BRAF inhibition in melanomas, The New 
England journal of medicine 364 772-774. 
[193] A. Boni, A.P. Cogdill, P. Dang, D. Udayakumar, C.N. Njauw, C.M. Sloss, C.R. 
Ferrone, K.T. Flaherty, D.P. Lawrence, D.E. Fisher, H. Tsao, J.A. Wargo, 
Selective BRAFV600E inhibition enhances T-cell recognition of melanoma 
without affecting lymphocyte function, Cancer research 70 (2010) 5213-5219. 
[194] M. Balsamo, F. Scordamaglia, G. Pietra, C. Manzini, C. Cantoni, M. Boitano, 
P. Queirolo, W. Vermi, F. Facchetti, A. Moretta, L. Moretta, M.C. Mingari, M. 
Vitale, Melanoma-associated fibroblasts modulate NK cell phenotype and 
antitumor cytotoxicity, Proc Natl Acad Sci U S A (2009). 
[195] Y. Li, S. Liu, J. Hernandez, L. Vence, P. Hwu, L. Radvanyi, MART-1-Specific 
Melanoma Tumor-Infiltrating Lymphocytes Maintaining CD28 Expression 
Have Improved Survival and Expansion Capability Following Antigenic 
Restimulation In Vitro, J Immunol 184 452-465. 
[196] C. Wellbrock, L. Ogilvie, D. Hedley, M. Karasarides, J. Martin, D. Niculescu-
Duvaz, C.J. Springer, R. Marais, V599EB-RAF is an oncogene in 
melanocytes, Cancer research 64 (2004) 2338-2342. 
[197] S. Pounds, S.W. Morris, Estimating the occurrence of false positives and false 
negatives in microarray studies by approximating and partitioning the 
empirical distribution of p-values, Bioinformatics 19 (2003) 1236-1242. 
 
 
  
	  178	  	  
VITA 
 
The author Jahan Salar Khalili was born in Olathe, Kansas on May 31st of 1981 to 
Besty and James Khalili Ph.D. and attended a local high school where he primarily 
built Rube Goldberg machines. After which he moved to Portland, Oregon to attend 
Reed College in 1999. At Reed College he completed a senior thesis under the 
mentorship of Laurens Rubens Ph.D. related to the expression of costimulatory 
proteins on cancer cells. During the off months of his college years, he worked in 
Kansas City, Missouri in the lab of Wayne Moore M.D. Ph.D. and Karen Kover 
Ph.D. on the subject of immune modulation in the context of islet transplantation. 
Upon completion of a Bachelor of Arts in Biology in May 2003 he moved to Seattle 
Washington to work at the T cell therapy company, Xycte Therapies under the 
guidance of Mark Bonyhadi Ph.D. until 2005. He attended the Graduate School of 
Biological Sciences at the University of Texas at Houston in pursuit of a Ph.D. in 
Immunology in Patrick Hwu’s group in the Department of Melanoma Medical 
Oncology as a member of the lab of Gregory Lizee Ph.D.. 
 
Publications and Patent:  
 
Khalili, J., Liu, S., Rodríguez-Cruz, T., Whittington, M., Wardell, S., Liu, C., Chen, 
J., Zhang, M., Li, Y., Joseph, R., Ekmekcioglu, S., Grimm, E., Radvanyi, L., Davies, 
M., Hwu, P. and Lizée, F., Inhibition of B-RAF (V600E) Relieves IL-1 Mediated T-
Cell Suppression by Melanoma Tumor-Associated Fibroblasts (submitted) 
	  179	  	  
 
Rodriguez-Cruz, T. Liu, S, Khalili, J. Whittinton, M. Zhang, M. Jefferies, W., Lizee 
G. Natural splice variant of MHC Class I cytoplasmic tail facilitates enhanced DC-
induced CD8+ T cell responses and boosts anti tumor immunity. 2011 PLoS ONE 
6(8): e22939. doi:10.1371/journal.pone.0022939 
 
Li, D., Li, Y., Hernandez, J. A., Patenia, R., Kim, T. K., Khalili, J., Dougherty, M. C.,  
Hanley, P. J., Bollard, C. M., Komanduri, K. V., Hwu, P., Champlin, R. E., Radvanyi,  
L. G., Molldrem, J. J. & Ma, Q. 2010. Lovastatin inhibits T-cell proliferation while  
preserving the cytolytic function of EBV, CMV, and MART-1-specific CTLs. J  
Immunother, 33: 975-82. 
 
Kim, T. K., St John, L. S., Wieder, E. D., Khalili, J., Ma, Q. & Komanduri, K. V.  
2009. Human late memory CD8+ T cells have a distinct cytokine signature  
characterized by CC chemokine production without IL-2 production. J Immunol,  
183:6167-74. 
 
Wang, Y., Li, D., Jones, D., Bassett, R., Sale, G. E., Khalili, J., Komanduri, K. V., 
Couriel, D. R., Champlin, R. E., Molldrem, J. J. & Ma, Q. 2009. Blocking LFA-1 
activation with lovastatin prevents graft-versus-host disease in mouse bone marrow 
transplantation. Biol Blood Marrow Transplant, 15: 1513-22. 
 
Voo, K. S., Wang, Y. H., Santori, F. R., Boggiano, C., Arima, K., Bover, L.,  
	  180	  	  
Hanabuchi, S., Khalili, J., Marinova, E., Zheng, B., Littman, D. R. & Liu, Y. J. 2009.  
Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl  
Acad Sci U S A, 106: 4793-8. 
 
Long, S. A., Khalili, J., Ashe, J., Berenson, R., Ferrand, C. & Bonyhadi, M. 2006.  
Standardized analysis for the quantification of Vbeta CDR3 T-cell receptor diversity.  
J Immunol Methods, 317: 100-13. 
 
CCR4 Therapeutic Antibody Patent: Method of treating B-cell neoplasms or 
Hodgkin's lymphoma. Publication number: US 2007/0172476. A1  
Inventors: Ryuzo Ueda, Takashi Ishida, Shiro Akinaga, Toshihiko Ishii, Daniel M. 
Jones, Richard J. Ford, Jahan Khalili, Kaushali Patel Assignees: Kyowa Hakko 
Kogyo Co., Ltd., Board of Regents, The University of Texas System  
 
Herling, M., Patel, K. A., Khalili, J., Schlette, E., Kobayashi, R., Medeiros, L. J. &  
Jones, D. 2006. TCL1 shows a regulated expression pattern in chronic lymphocytic  
leukemia that correlates with molecular subtypes and proliferative state. Leukemia,  
20: 280-5.  
 
Noonan, K., Matsui, W., Serafini, P., Carbley, R., Tan, G., Khalili, J., Bonyhadi, M.,  
Levitsky, H., Whartenby, K. & Borrello, I. 2005. Activated marrow-infiltrating  
lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer  
Res, 65: 2026-34. 
	  181	  	  
 
Moore, W. V., Chu, W., Tong, P. Y., Hess, D., Benjamin, C., Khalili, J. & Kover, K.  
2002. Prevention of autoimmune diabetes in the DRBB rat by CD40/154 blockade. J  
Autoimmun, 19: 139-45. 
 
